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Abstract 
 
Cervical cancer screening and prevention has been one of the great 
success stories in public health, but is at a critical juncture.  Awareness of the 
essential role of HPV infection in the genesis of cervical cancer, coupled with 
knowledge of the limitations of cytology has led to a re-visioning of the screening 
paradigm, towards the use of primary hr-HPV testing for cervical cancer 
screening instead of cytology. Use of HPV testing could result in significant 
changes for screening programs including a later start to screening, extended 
screening intervals, and use of a test for a sexually acquired infection. These 
changes may have unintended consequences on a woman’s willingness to 
participate in cervical cancer screening.  In this dissertation, we explore the 
potential impact of use of HPV testing for primary screening on women’s 
intentions to be screened for cervical cancer, and outline a plan to guide the 
change from cytology to HPV testing, using findings from the analyses.   
Methods: At study exit, a sample of participants from a randomized trial of 
primary hr-HPV testing in Canada were invited via email to complete an 
electronic questionnaire based in Theory of Planned Behaviour, which 
determined women’s intentions to be screened for cervical cancer if: a) hr-HPV 
was used instead of Pap smears b) HPV based cervical cancer screening was
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 offered only every 4 years and c) HPV based cervical cancer screening started 
after 25 years of age.  Demographic data, sexual history and smoking rates were 
assessed, and scales for attitudes about hr-HPV testing, perceived behavioural 
control and direct and indirect subjective norms were created.  
Item correlation for scales was calculated to determine item agreement. 
Univariate analyses compared demographics and scale responses of women 
who intended to be screened for cervical cancer with HPV to those who did not. 
All demographic data and scales that were significantly different (p<0.1) were 
included in a stepwise logistic regression model to determine predictors of 
intention to be screened for cervical cancer with HPV.   
Results: 2016 email invites were sent to women and 981 completed the 
entire survey for a response rate of 48.7%.  There were no demographic and risk 
behavior differences between survey respondents and non-respondents. Eighty-
four percent of women (826/981) responded that they intended to attend for 
HPV-CCS which decreased to 54.2% with an extended screening interval, and 
decreased further to 51.4% with a delayed start of age 25. There were not 
significant differences in demographics, sexual or smoking histories between 
women who intended to be screened for cervical cancer with HPV and those who 
did not intend. Women who intended to be screened with HPV were significantly 
more likely to report positive attitudes toward HPV testing, report positive 
perceived behavioural control, describe positive influence of direct and indirect 
subjective norms, and express confidence in their decisions and abilities to 
communicate their HPV status with partners.  In logistic regression modeling, 
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predictors of intentions to undergo screening were attitudes (OR 1.22; 95%CI 
1.15, 1.30), indirect subjective norms (OR 1.02; 95%CI 1.01, 1.03) and perceived 
behavioural controls (OR 1.16; 95% CI 1.10; 1.22).  
Discussion: Although women expressed intentions to be screened for 
cervical cancer with HPV, intentions decreased substantially when coupled with 
the extended screening interval and delayed screening start. Use of primary HPV 
testing may optimize the screening paradigm, but programs must anticipate 
women’s potential responses and concerns with program changes, such as 
extended intervals and delayed program starts, and should ensure robust 
planning and education to mitigate any negative impact on screening attendance 
rates. Using Kotter’s eight step model and integrating key findings from this 
study, essential elements to successfully implement this change are outlined.   
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CHAPTER 1: Introduction 
 
Cervical Cancer and Human Papillomavirus 
Cervical cancer screening using cervical cytology (the Pap smear) has 
been an extremely successful public health intervention, achieving reductions in 
cervical cancer incidence of up to 80% where practiced effectively (1). However, 
the Pap smear was introduced over 50 years ago, and studies have now proven 
that, despite its substantial contributions, as a screening tool it has significant 
limitations. Data from some jurisdictions indicate that cervical cancer rates have 
reached a nadir, and meta-analyses indicate that the sensitivity of a single Pap 
test to detect cervical intraepithelial neoplasia (CIN) or invasive cervical cancer is 
less than 60%(2).   
There is now ample evidence that infection with high-risk types of the 
human papillomavirus (hr-HPV) is a requisite step for the development of cervical 
cancer and its precursors (3;4). Of the over 100 subtypes of human 
papillomavirus, fifteen of these, including types 16 and 18, are high risk types 
and are known to be the necessary causes of cervical cancer(3). HPV is primarily 
acquired through sexual contact, but unlike other sexually acquired infections, 
HPV is exceedingly prevalent, and the cumulative lifetime prevalence of HPV in 
women is over 75% (5).  It is a highly transmissible virus, and the majority of
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women acquire cervical HPV infections with at least one type of HPV within 2 to 
5 years after initiating sexual activity(6).  Usually, however, HPV is a transient 
infection; over 90% of women clear incident cervical HPV infections within 2 
years of acquisition (7;8).  Women who do not clear HPV infections are at risk for 
developing persistent HPV infections and, potentially, pre-cancerous cervical 
lesions (CIN1, CIN2, CIN3) which may then progress to cervical cancer if not 
treated(9). Every year in British Columbia, more than 500,000 women are 
screened for cervical cancer through the cervical cancer screening program, 
more than 5,000 are treated for CIN2/3, and 100 develop HPV16/18 related 
cervical cancers (10).  Although the overall rates of cervical cancer may appear 
low, these are only achieved because of extensive, sustained efforts with 
screening and treatment, of several thousands of women with pre-cancerous 
lesions using ablative and excisional therapies. 
As a primary screening tool, cross-sectional studies have shown that hr-
HPV testing has higher sensitivity and negative predictive value (NPV) for CIN2 
or worse (CIN2+) detection than either the conventional Pap smear or liquid 
based cytology (LBC), albeit with lower specificity and positive predictive value 
(PPV)(11-16). In recognition of this, one approach for screening would be to use 
hr-HPV testing as a single primary screening test, with cytology reserved only for 
triage of women having a positive test.  This is particularly relevant for vaccinated 
populations, where, especially following the advent of HPV vaccination, we can 
expect to see a degradation of the performance characteristics of cytology, 
including a reduction in the positive predictive value of cytology(17). HPV testing 
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in this setting has screening performance characteristics that would make it an 
ideal primary screening test for cervical cancer. 
To examine these concepts, several large, international randomized 
controlled trials (RCT) are being conducted in Europe and Canada to evaluate 
HPV testing as part of primary cervical cancer screening (13;18-25).  With the 
exception of the Finnish Randomized Public Health Trial and phase 2 of the New 
Technologies for Cervical Cancer Screening (NTCC) trial in Italy, these trials 
compared combined HPV and cytology testing and cytology alone as the primary 
screening intervention.  Phase 2 of NTCC, the Canadian HPV Focal Trial and the 
Finnish trials are comparing HPV versus cytology as the primary screen, with 
follow up cytology. These trials all examine clinically relevant endpoints of CIN2+ 
and CIN 3+.  Data from these trials show that use of hr-HPV as a primary screen 
improves detection of CIN2+, and also prevents more cancer than cytology (26-
28).  
Cervical cancer screening programs across jurisdictions in Canada and 
Europe are now poised to make a substantial paradigm shift to consider the use 
of hr-HPV testing as the primary screen for cervical cancer(29-31).  However, 
successful screening programs should consider factors beyond attributes of the 
screening test.  To date, emphasis on use of hr-HPV testing in cervical cancer 
screening has focused on diagnostic accuracy and clinical outcomes of the 
screening modalities.  There are other, broader considerations that should be 
examined.  Introduction of primary HPV testing would be a paradigm shift in a 
long established screening program which for many women is a rite of passage. 
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Use of HPV testing as a primary screen could lead to changes in both the timing 
of testing and implications of positive test results, which would have impacts on 
the acceptability, uptake and ultimately the success of the screening program.  
Experiences with colorectal cancer screening have demonstrated that 
implementation of screening tools should be considered in a broad sense, 
beyond the sensitivity and disease detection capabilities of the screening 
protocol.  Colorectal cancer is the second most common cause of cancer death 
in Europe, Australia and the United States, and screening interventions have 
proved to be effective in reducing colorectal cancer mortality (32).  Screening 
consists of faecal occult blood testing followed by colonoscopy, if warranted.  
Colonoscopy is a relatively invasive procedure, where a thin fibre-optic camera is 
inserted into the rectum and then into the large bowel.  The clinician can then 
visualize both the rectal and bowel tissue and biopsy if any areas of concern are 
noted.  In order for colonoscopy to be completed successfully, patients must 
complete bowel preparation in advance. Many patients find this uncomfortable 
and inconvenient.  Combined, both the bowel preparation and the actual 
colonoscopy can be an unpleasant experience for patients, and has led to 
challenges with acceptance of colorectal screening.  In a comprehensive review, 
although rates for surgery for colorectal cancer have increased in the United 
States, up to 20% of individuals with abnormal faecal occult blood testing did not 
proceed to colonoscopy after initial screening (32).  When explored in further 
detail, patients were reluctant to undergo colonoscopy due to discomfort with the 
bowel preparation, as well as anxiety with the test, anticipation about pain and 
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complications.  Women in particular articulated embarrassment and feelings of 
vulnerability. Suggested actions included development of improved bowel 
preparation processes as well as focusing on comfort during the procedure and 
providing comprehensive education to alleviate anxiety in order to improve the 
uptake rate of colonoscopy.  The importance of client education and knowledge 
about the value of colonoscopy were identified as key opportunities to improve 
uptake and finally physician recommendation was a critical factor in influencing 
the uptake of colonoscopy.   
Practitioners and policy makers need to be mindful that simply because a 
screening intervention is effective clinically, this is not sufficient to ensure 
successful acceptance and implementation.  However, screening for colorectal 
cancer has been successful in many countries, demonstrating that even if a 
screening intervention itself is of some concern for clients, they can be 
successfully adopted and utilized in a health care system to improve health 
outcomes, when attention is paid to the potential client issues..  As colorectal 
screening has shown, program implementation with consideration of broader 
issues can lead to a high acceptability of the procedure and screening 
intervention.  Thus, careful reflection of the broader implications of moving to hr-
HPV testing as a primary screen for cervical cancer on the structure and 
acceptability of cervical cancer screening is essential; to anticipate how the 
change in the test used might impact on this long established screening program.   
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HPV testing has specific elements that, if employed, will impact on the structure 
and delivery of cervical cancer screening.  Because hr-HPV testing offers 
improved sensitivity for detecting precancerous lesions, a negative test offers 
greater assurance to clinicians and screening participants that they are not at risk 
for developing cervical cancer in the near future.  Recent reviews by Dillner (14) 
have proposed that screening intervals for hr-HPV negative women could be 
extended to five years, yet still offer effective and safe screening for cervical 
cancer precursors. If hr-HPV testing were offered in British Columbia, women 
who have been accustomed to receiving annual screening may be advised and 
possibly limited to cervical cancer screening every five years.   
In addition, hr-HPV testing is based more in the true natural history of 
cervical cancer dysplasia and lesions, and screening with hr-HPV may permit a 
delay in the age at which women begin to be screened for cervical cancer.  HPV 
is an exceedingly prevalent infection, and the majority of women clear the 
infection on their own.  However, in women who do not clear their infections, 
there is a risk for development of precancerous cervical lesions and possibly 
cervical cancer. Given the prevalence of HPV, particularly in young women, 
testing for cervical cancer using HPV in women under 25 will identify an 
extensive number of lesions that will most likely regress, and thus limit the value 
of the screening test by diminishing the test’s specificity. For hr-HPV testing to be 
useful, it should detect primarily persistent, as opposed to transient lesions.  To 
minimize false positives, cervical cancer screening using hr-HPV testing likely will 
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be delayed until after age 25 and possibly even later, to ages 30, which is more 
aligned with current European practices. 
The final challenge of the shift to HPV testing is that from an oncological to 
a communicable disease paradigm.  Cytology identified cellular changes 
associated with precancerous lesions in the transition zone of the cervix.  In 
contrast, HPV testing identifies the infection that precipitates these changes in 
the transition zone.  However, HPV itself is an infection that is sexually acquired.  
Despite the fact that the infection is highly prevalent, use of hr-HPV testing as the 
screen for cervical cancer will require practitioners to provide women, many of 
whom have been in monogamous relationships, with information that they are 
infected with a sexually acquired virus.  Even though the virus may have been 
acquired many years prior, doubtless this will offer significant challenges both for 
practitioners and for patients.  Since practitioners will be counselling women 
about a sexually transmitted infection, they will need to manage the anxiety, guilt 
and shame that may follow(33). 
Since cervical cancer screening using cytology is one of the most 
established and integrated health services screening programs, clinicians, 
researchers and policy makers should systematically examine potential impacts, 
both positive and negative, of a change from cytology to hr-HPV testing on 
attendance for and uptake of cervical cancer screening.  As one of the most 
effective types of screening, it is essential to determine if the switch from cytology 
to hr-HPV testing has negative effects on the uptake rate for cervical cancer 
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screening. If that occurs, policies, education and interventions to attenuate any 
projected uptake reductions will be required.   
 
Context for research question 
British Columbia is the western-most province of Canada, with a 
population of 4 million.  Health care in the province is publicly funded, and cancer 
care in the province is centralized with one agency, the British Columbia Cancer 
Agency, primarily responsible for establishing screening guidelines and for 
service delivery of cancer care throughout the province.  The cervical cancer 
screening program of the BCCA is one of the longest established screening 
programs.  Over 750,000 Pap screens are conducted in the province yearly, and 
one central laboratory analyzes all Pap smears.   
In British Columbia, all recommendations for cancer screening and cancer 
care are made by the British Columbia Cancer Agency (BCCA) Tumour Group, 
an interdisciplinary panel of appointed experts, who review recommendations 
based on advice from focused task groups.  Currently, the British Columbia 
Cancer Agency recommends that women be screened for three years annually 
using cytology, and then every two years, if the initial three screenings are 
negative. Even with these recommendations, many women still are screened 
yearly. As British Columbia begins to consider a change from cytology to hr-HPV 
testing, a comprehensive examination of the impact of such a change specifically 
on women’s intention and willingness to be screened for cervical cancer is 
required. 
 
 
CHAPTER 2: Study roles, responsibilities and chronology 
 
This dissertation has two parts: secondary analysis of a survey conducted 
as part of the HPV FOCAL trial and a plan for change to implement cervical 
cancer screening based on HPV testing.  The HPV FOCAL trial is a randomized 
trial based in British Columbia with the primary objective of comparing the 
efficacy of cytology to hr-HPV testing as the primary screen for cervical cancer.  
The Doctorate of Public Health candidate, Dr. Gina Ogilvie, is co-principal 
investigator for the HPV FOCAL trial. HPV FOCAL trial is funded by Canada’s 
national health research agency, the Canadian Institutes for Health Research.   
HPV FOCAL began recruitment in late 2007, and recruitment of 28,000 
women was completed in April 2012.  By January 2010, ~ 2000 women who had 
been randomized to the safety check arm had completed the trial. As part of 
exiting the trial, women were invited to complete a survey on a variety of topics, 
including acceptability of self-collection, experience in the clinical trial and their 
intentions to receive cervical cancer screening based on HPV testing.  The 
investigator team of HPV FOCAL designed and implemented the survey. For this 
dissertation, the Doctorate of Public Health candidate analysed survey data 
relevant to intentions to receive cervical cancer screening using HPV.
 
 
CHAPTER 3: Literature Review 
 
Substantial changes in health care programs require health policy to 
provide the foundation for the change, leadership and engagement from the 
system to support the program, from practitioners, as advocates and experts to 
deliver the intervention and from the patients, who ultimately must accept and 
make the decision to be screened. Evidence shows that all of these elements 
must be aligned in order for a program to be successfully implemented. For 
purposes of this dissertation, the focus will be on one of these elements: the 
factors that facilitate acceptability and intention to be screened for women for 
cervical cancer using hr-HPV testing.  Ultimately however, for system change to 
be effective, the broader elements of policy, system support and practitioner 
engagement must all be aligned and working in concert to achieve the paradigm 
shift. 
As part of this inquiry, we examined the scientific literature broadly to 
determine women’s experiences and concerns about HPV testing as well as the 
impact of the proposed use of hr-HPV testing on women’s intentions and uptake 
of cervical cancer screening services.  Following this, to specifically align with our 
focused research question, we conducted a systematic literature review to 
determine if there is any evidence that:  i) extension of the screening interval ii) 
delay of screening initiation and iii) use of a test for a communicable disease 
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have an impact on intentions or actual attendance for cervical cancer screening 
in North American women.   
 
Search Methods 
The search was conducted using standard search procedures in 
‘PubMed’, a free database maintained by the U.S. National Library of Medicine 
and the National Institutes of Health that accesses MEDLINE and other 
biomedical databases. PubMed was searched using the key words [‘attitude’ OR 
‘knowledge’ OR ‘acceptability’ OR ‘intention’] AND human papillomavirus (HPV).  
Given the rapid pace of development for HPV testing, the search was limited to 
studies published from 2002 until December 2011 and to English language 
studies.  Key words ‘screening’, ‘cervix’, ‘vaginal smears’ were not used for this 
search, since use of these words might limit search results unnecessarily, given 
the nascent nature of this field. 
Inclusion and exclusion criteria 
Both qualitative and quantitative studies that surveyed or interviewed 
females who routinely attended cervical cancer screening (> =15 years of age 
and <= 70 years of age) about their knowledge of and/or attitudes towards the 
use of HPV testing and/or intentions to screen if hr-HPV testing was used for 
cervical cancer screening were included. Studies using a variety sampling 
techniques, including random digit dialing, convenience, clinic based, venue 
based and population- based also were included.  Studies that were completed in 
person, by mail, telephone-based, or online also were included. There was no 
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restriction for study inclusion based on country where the study was conducted, 
as long as the study was published in English.  
As outlined earlier, although the role of practitioners, policy and systems 
are critical elements in success of a change in implementing screening 
programs, for purposes of this dissertation, the focus is on acceptability and 
intentions to be screened from the perspective of women.  Thus, studies that 
assessed attitudes of practitioners, peers or policy makers as were studies that 
examined attitudes to the HPV vaccine alone (and not HPV testing) or to 
attitudes about HPV in men were not included. 
  
Criteria for inclusion included: 
1. Participants: Female  
2. Age: 15-70 years 
3. Study Objective: Examine women’s attitudes towards OR acceptability of 
HPV testing as a primary method for cervical cancer screening; To 
examine women’s intentions to be screened for cervical cancer with hr-
HPV testing 
4. Analysis technique: Qualitative or quantitative 
 
Using ‘PubMed’ and following the search strategy listed above, the following 
results were obtained: 
Key words: ‘attitude’ OR ‘knowledge’ OR ‘acceptability’ OR ‘intention’: 489,771 
articles 
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Limit: English, < 5 years: 148,872 articles 
Human Papillomavirus: 483 articles 
 
In the end, 483 articles were identified through the search strategy and 
sixty-eight articles were selected for review: None of the studies examined 
extension of cervical cancer screening from annual or bi-annual screening.   
 
I. Intention and willingness to be screened with HPV-DNA  
In a qualitative study of Hispanic women aged 18 to 60, Vanslyke et al. 
(34) used focus groups with women from community-based organizations to 
discuss cervical cancer, HPV testing and prevention.  Fifty-four women were 
recruited, and seven focus groups with 5 to 11 participants each were conducted 
in both English and Spanish.  Data analyses were not based on pre-specified 
frameworks, but were derived from the data.  For this phenomenological study, 
the researchers transcribed and translated all the focus groups and underwent 
translation verification. Two researchers read the transcripts and organized data 
to identify themes related to cervical cancer and Hpv testing.  Data was coded 
and then the team met to come to consensus on the coding scheme and identify 
major themes.  Vanslyke found that there was a range in willingness for women 
to participate in HPV DNA testing.  Responses ranged from an intention to be 
screened for cervical cancer to a belief that there is no need for HPV testing.  
Those who intended to be screened for cervical cancer said they wanted to know 
how to get treatment, while those who were unsure or unwilling said they were 
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reluctant to receive a cancer or HPV diagnosis. Participants also expressed 
concern about the meaning and implications of a positive test.  Regardless of a 
women’s perspective on HPV testing, all stressed the need for expressed 
consent regarding the meaning of the test. 
Strengths of this study include the broad age range of the participants 
included, which mirrors the majority of women who seek and are recommended 
for cervical cancer screening.  Women who often do not attend for screening 
(Spanish speaking, low income) specifically were recruited for this study, which 
can help broadly inform approaches to improve recruitment into screening for 
women known to be at higher risk for cervical cancer. By employing a focus 
group methodology, participants are encouraged and supported to explore 
broader conceptualization than with individual interviews. This study deliberately 
explored a very important area that will inform future programming for cervical 
cancer screening with the question ‘How would you feel about being tested for 
HPV?’ However, this exploratory study of the phenomena of HPV testing did not 
develop nor test a theoretical or conceptual framework for understanding HPV 
testing. The authors identified their findings as a foundation for future areas of 
future research and examination.  
As part of an omnibus survey from the National Centre for Social 
Research conducted between November 2006 and February 2007, 994 women 
aged 25-64 women in Britain were asked about acceptance of HPV testing. 
Specifically, they were asked how likely they would be to accept an HPV test if 
offered one at their next cervical cancer screening appointments. Overall, 70% of 
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women said they were willing to accept HPV testing as cervical cancer 
screening.  In multivariate modeling, screening attendance, Caucasian ethnicity 
and talking to friends about female health issues were significant predictors of 
intention to receive hr-HPV testing for cervical cancer screening (35). 
This study relied on an existing national recruitment methodology for a 
population based survey and is not based in a specific theoretical model.  The 
survey explored a broad range of health questions, and included specific 
questions about HPV screening based on five point Likert scales.  Variables 
relevant to cervical cancer screening attendance and uptake, including age, 
ethnicity and education level, were available on all participants.  It also included 
the precise target range for cervical cancer screening.  However, the study was 
limited by reliance on the pre-existing items in the survey.  In addition, the 
author’s commented that specific minorities (6% vs. UK population of 8%) were 
under-represented, limiting their ability to examine detailed differences between 
specific ethnic minorities.  As ethnicity is an important predictor of cervical cancer 
screening in general, this study could have provided very useful information for 
policy makers, given the existing differences in screening uptake in different 
cultural and ethnic groups. 
In Huang’s evaluation of 865 older women aged 50 to 80 who were 
educated about HPV (including the fact that it is sexually transmitted), 64% 
indicated an interest in HPV testing (33).  This study did not look at extended 
HPV testing intervals, but participants indicated a willingness to have Pap testing 
every three years rather than ever year if they had a previous negative HPV test.  
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Over 75% said they would have more frequent Pap testing after a positive HPV 
test. 
The study was embedded in and thus benefitted from an established, well-
designed community-based cross-sectional study.  The study was designed to 
evaluate cancer perceptions in women from four racial and ethnic groups (white, 
Latina, African American and Asian).  Participants were recruited from a wide 
range of primary care clinics in San Francisco and offered questionnaires in 
multiple languages to ensure a broadly representative sample.  A limitation of this 
study was that it did not include women outside the health system. The authors 
also did not describe a theoretical framework for their survey.  These findings are 
very relevant for the proposed research, as they it offers important information on 
HPV testing in an older cohort.  That said, the very specific ethnicity of the 
participants will offer some limitations to generalizability of findings. 
Kwan (36) developed an intervention with the goal of reducing HPV-
related stigma in the Chinese community.  In a randomized controlled trial of 
HPV message testing, Kwan applied different foci for messaging around HPV, 
varying information and stress on prevalence, sexual acquisition and risk for 
cancer in women older than 18. Participants were assigned to read information 
about HPV from one of three theme groups, and completed a survey before and 
after the informational intervention. Prior to receiving the educational intervention, 
90% of the 294 ethnic Chinese women who participated stated they would 
receive HPV testing.  After messaging, overall, 97% stated they would get HPV 
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testing as part of cervical cancer screening.  The increase in positive intention to 
participate was significant (p<0.05), and this was found across all three arms. 
The study provided insights about women’s intentions to receive high risk 
HPV testing both pre and post HPV education.  It used items that showed good 
reliability, and the survey instrument was pilot tested and revised.  Sample size 
calculations were clearly presented, and the rationale for statistical analyses was 
cogent. There were some limitations to this study. No theoretical framework for 
study design and approach was presented.  Also, the study only included women 
who could read Chinese, which could limit generalizability of study findings to 
literate women.  The study recruited solely from the Family Planning Association 
of Hong Kong for birth control.  This would bias findings towards women who 
potentially had more sexual partners and were not in steady relationships, which 
would potentially limit the generalizability of the findings to a broad screening 
population.  
 
II. Impact of a positive HPV test 
Waller et al. (37) conducted a web-based survey of 811 female students in 
the United Kingdom.  They were asked to imagine that they received a positive 
HPV test and then answered a series of questions regarding stigma, shame and 
anxiety (in keeping with experience of other positive STIs).  Stigma, shame and 
anxiety were significantly lower when women were aware that HPV is a highly 
prevalent virus (p<0.05).  Knowledge that HPV is sexually transmitted was 
associated with higher levels of stigma and shame, but not anxiety (p=0.001).  
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Lack of awareness of the prevalence of HPV, but awareness of its sexually 
acquired nature was associated with high scores for stigma and shame.   
Strengths of this study include use of a survey that is based on 
established theories and was adapted from previous instruments and qualitative 
work. The method of distribution and recruitment model was highly appropriate 
for the age of the participants.  However, because only women under the age of 
30 were recruited it would be challenging to generalize findings of this study to a 
broad screening population.    
In our literature search, four studies were identified in the past five years 
that examined women’s willingness to be screened with hr-HPV instead of 
cytology. No studies were completely consistent with our parameters.  In general, 
most reported that the majority of women were willing to receive HPV testing for 
cervical cancer screening. No studies looked at an extension of screening 
intervals or delayed screening, but included studies that assessed the 
acceptability of hr-HPV testing. Studies tended to explore particular subgroups, 
such as women over the age of 50 or women of Chinese background, and only 
one aimed to recruit a broad screening population. Women expressed the need 
to consent for the test and information regarding implications of a positive test.  
Messaging was an important aspect of test acceptability, and a focus on high 
prevalence of hr-HPV was key to acceptance of HPV testing and decreased 
stigma of HPV infection.   
Only one study explicitly examined the impact of positive HPV testing in 
the setting of a screening program.  In this study, shame and stigma were 
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assessed in the context of a positive HPV test in low risk women.  Some critical 
findings for HPV education emerged.  Women who were aware of the very high 
prevalence of HPV were less likely to report high levels of stigma, shame and 
anxiety.  However, women who were only aware of the sexually transmitted 
nature of HPV had high levels of stigma and shame.  This is likely related to the 
ongoing stigma that sexually acquired infections have in our society. 
No studies explored consequences of extended screening intervals on 
acceptability and intentions to receive screening with hr-HPV nor on delayed 
initiation of screening.  These are particularly important areas, as findings in 
related settings contrast regarding the implications of delayed and extended 
cervical cancer screening.  In a study of Pap screening (not HPV testing), 
Sirovich reported that women preferred to be screened annually, and 69% 
reported that they would try to continue to receive annual screening, even if 
advised for extended screening by their physicians. Women in this survey also 
believed that any extension in screening was based on cost constraints, not 
about best practice (38). In one study, women reported that they were willing to 
have extended cytology screening if they had a previous negative test.  This 
indicates that women need to be assured regarding accuracy of their screening 
results, in order to accept extended intervals.  The contradictory findings confirm 
the need for further research into the implications of extended screening intervals 
for women and educational interventions needed to effectively support these 
changes.  
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Perceptions and psychosocial reactions to an HPV diagnosis 
In qualitative and quantitative studies women reported a wide range of 
emotions and psychosocial reactions to receiving an HPV diagnosis. These 
reactions included anxiety, fear, distress and anger in response to a positive HPV 
test.  Women described anxiety about the impact of HPV results on their 
relationships, expressed concern about the need to disclose their results to their 
sexual partners and highlighted the importance of informed consent for HPV 
testing. Some women also felt empowered, because they could take action to 
mitigate the consequences of the infection (39).   
In an Australian study, women were anxious, distressed and confused by 
the diagnosis of HPV (40).  In an additional study of British women, McCaffery 
found that much of the distress for HPV testing related to stigma for sexually 
acquired infections, and that this transcended cultural groups.  McCaffery 
described ‘strong negative emotional responses’ to positive HPV tests. Women 
were concerned about the source of infection, and impact of a positive result on 
relationships, implications on mistrust, infidelity and promiscuity (41).  While 
Hispanic women also reported potential anxiety and distress with an HPV 
positive result, this same group also reported a wide range of acceptance for 
HPV testing, from willingness to receive an HPV test to reluctance(34).  
In a study of adolescents and how they process HPV results, there were 
four key dimensions for young women as they defined the personal meaning of 
positive HPV results.  Despite similar education, young women framed a positive 
HPV test result as either an STI or a cancer result.  Young women who labelled 
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the HPV result as an STI reported much guilt, shame and stigma. Perceived risk 
for cancer was influenced by an adolescent’s framing of the health risk and 
perceptions of control.  Stigma and shame were prominent components of the 
personal meaning that young women applied to positive HPV results.  In 
particular, adolescent women were more likely to understand an HPV infection 
compared to an abnormal Pap smear as stigmatizing, and expressed concern 
about social rejection.  Specifically, adolescents endorsed the belief that 
adolescents who had HPV infections would be perceived as promiscuous and 
likely co-infected with other sexually transmitted infections(42).   
In Waller’s study of university students, she found that awareness of HPV 
infection was associated with higher levels of stigma and shame (43). In this 
study, however, increased awareness of HPV did not lead to greater anxiety, 
perhaps because women who were aware of HPV were less focused on the HPV 
and cancer link compared to women with less knowledge about HPV.  At the 
same time, Waller noted that women reported lower stigma and shame scores 
when they were informed about the high prevalence of HPV. 
In in-depth interviews with women following HPV diagnoses, Daley et al. 
described five themes in their emotional responses: stigma, fear, self-blame, 
powerlessness and anger(44).  As a consequence of their HPV diagnosis, 
women reported reactions often associated with stress, including loss of sleep, 
loss of appetite and problems focusing on activities of daily living, but were they 
still were able to disclose their results to partners.  
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In another study of Hispanic men and women, Fernandez found that 
women had a range of reactions to HPV positive results, from fatalistic to stoic. 
Their responses focused primarily on the link of HPV with cancer, and thus their 
responses reflected responses to a perceived ‘cancer’ diagnosis, as opposed to 
an STI diagnosis or results of a screening test to be investigated further.  Women 
also focused on the impact on their families and economic consequences of a 
cancer diagnosis.  When discussing partners’ reactions, women said that their 
partners would be angry, question their fidelity and quite possibly may abandon 
them.  Women framed this in the machismo of Hispanic men, and most felt that 
their partners would believe the women had been unfaithful; few male partners 
would worry about the diagnosis being a reflection of their own potential infidelity 
(45).  
Canadian women from Ontario associated an HPV diagnosis with stigma, 
infidelity and immorality (46).  They described a reluctance to receive results and 
to share results with those around them.  However, their anxiety about the 
implications of results did not appear to deter women from having HPV tests, and 
they welcomed the opportunity to have a screening test that provided more 
definitive results for them and their practitioners which could more accurately 
guide their follow up procedures.  As with previous studies, women highlighted 
the need for confidentiality and also the opportunity to consent and control their 
access to the test results. 
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In another study of women who received positive HPV test results, Waller noted 
reactions of shock, confusion, distress about the diagnosis (47).  These reactions 
were centred on the sexually transmitted nature of the virus, and the potential 
source of the virus from their partners.  When women experienced a persistently 
positive HPV result a year later, women’s anxiety was heightened, as women 
realized that there may not be a resolution to the infection, and they may require 
further investigation and treatment.  At this point, women described concerns 
about cancer, fertility and again focused on the sexually transmitted nature of the 
infection and its potential impact on their relationships.  They also expressed 
disappointment that the infection had not cleared on its own, as they had hoped, 
and so were realizing that the infection was more serious than they initially 
believed.  Disclosing results in this study created comfort for some women, as 
they found reassurance and support in their friends and family.  However, for 
others, disclosure was not helpful, because their support networks were unaware 
of HPV, or women felt guilty that they had potentially infected their partners.  
In a study with co-testing for HPV and cytology, women with abnormal 
Pap smears who also were HPV positive reported higher levels of anxiety, 
distress and concern compared to women with abnormal or normal smear 
results(48).  The anxiety rates were higher when women perceived themselves to 
be at higher risk for developing cervical cancer. In their follow up study 6 months 
later, the authors found a diminished level of anxiety in the women who were 
positive, but these women still had heightened level of concern about the test 
results(49).  Specifically, predictors of heightened concerns were associated 
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mainly with ongoing worries about developing cancer, as well as HPV status, 
history of abnormal smears and sexual health concerns.  
In this literature review, we examined published data to determine if there 
is any evidence that demonstrates if  i) an extension of the screening interval ii) 
delay of screening commencement and iii) use of a test for a communicable 
disease has an impact on intentions to participate in cervical cancer screening in 
North American women.  Despite widespread use of cervical cancer screening, 
and its position as a central pillar in routine health maintenance, there has been 
relatively little work conducted on the impact of changing screening modality.  
This literature review has demonstrated that a preliminary body of work has been 
conducted on acceptability of the HPV vaccine and considerable work has been 
done on women’s knowledge, attitudes towards HPV testing as well as their 
experiences receiving HPV results both theoretically and in reality.  However, few 
researchers have taken the next step to deliberately and methodically apply a 
theoretical framework and inquire from women as to whether they would continue 
receiving this important health intervention when paradigms shift.  This is a 
concerning omission, as the focus of research seems to have been primarily on 
the diagnostic accuracy and characteristics of the new testing intervention with 
little consideration of how these new tests will impact the use of cervical cancer 
screening broadly.  Research is urgently needed, as the clinical data confirming 
the utility of hr-HPV for screening expands, to ensure that implementation of this 
change in screening modality is conducted in an effective and patient centred 
fashion. 
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Need for studies situated in Behavioural Models 
Future studies in this field should be grounded in established theoretical 
models that examine health care seeking in individuals, such as the Theory of 
Planned Behaviour or Health Belief Model (50).  Research should be focused in 
particular on use of hr-HPV testing in screening paradigms (as opposed to case 
finding or follow-up of abnormal cytology). Implications for asymptomatic, low risk 
women are different from women who report symptoms or have abnormal test 
results.  Both qualitative and quantitative work should be conducted.  Population 
based studies that examine key elements such as intention to receive screening 
if hr-HPV testing is used and the potential impact of extended screening intervals 
should be conducted.  These population-based quantitative studies should 
include a broad range of women who both participate and do not participate in 
cervical cancer screening. Women should be asked how a change in testing 
modality would impact their future intentions to participate in screening.  
Qualitative work should examine women’s perceptions around hr-HPV testing 
and their concerns and worries about extended screening intervals and use of a 
test for sexually acquired infections.  Women also should be asked how 
educational programs and clinicians can best allay their fears about the use of hr-
HPV testing.  There should also be deliberate examination of populations known 
to have low rates of cervical cancer screening (aboriginal women, immigrant 
women, African-American women) to determine if this shift in screening modality 
can enhance their participation in screening programs.  
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One of the main limitations of previous studies regarding the acceptability 
and impact on intentions of a new screening paradigm is that they were not 
grounded in models of health behaviour.  Ultimately, information from the 
proposed research will be used to inform program and policy planning for 
implementation of a new screening program.  It is prudent and advantageous and 
will improve the rigour of findings if inquiries are based on established theoretical 
models.  By using a framework, planners can move beyond intuition and develop 
programs that are based on a more refined understanding of health behaviour.  
Several reviews have shown that interventions based on theories were more 
effective than those not based on a theoretical framework.  Thus, considering 
theories from the start of planning programs designed to promote health seeking 
behaviours will likely to improve their success. 
No single theory dominates health promotion research and education on 
health behaviour.  Several prominent theories are used to understand why 
individuals participate in behaviours that promote health, such as cancer 
screening. Using theoretical foundations, researchers can better parse out both 
the behaviour and the specific elements that underpin behaviours. Broadly, 
theories can be understood as explanatory or change theories, which focus on 
different aspects of behaviour, but contribute in complementary way to planning. 
In a recent systematic review, the most frequently used theories used for 
examining health promotion are social learning theory, theory of planned 
behaviour and the health belief model.  
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The theory of planned behaviour (TPB) is a well-described theory of 
human behaviour and has been used extensively to look at screening health 
behaviours, such as mammography (51).  It is based on Ajzen’s and Fishbein’s 
Theory of Reasoned Action (TRA), which is particularly valuable to describe 
behaviours that are under an individual’s volitional control. The theory of planned 
behaviour, and its predecessor TRA describes intention as the most proximate 
predictor of behaviour.  In turn, three specific elements predict intentions: attitude 
towards the behaviour, perceived behavioural control and subjective norms to the 
behaviour.  Initially, with TRA, Ajzen and Fishbein described attitude toward the 
behaviour in question as well as the subjective norms to the behaviour (an 
individual’s belief about how people they care about will view the behavior in 
question.)  To predict someone’s intentions, knowing these beliefs can be as 
important as knowing the person’s attitudes.  As the TRA was developed, Ajzen 
added an additional dimension, perceived behavioural control, to capture an 
individual’s ability to control the behaviour.  This new theory was named the 
Theory of Planned Behaviour(51).  
For purposes of this study, we will use theory of planned behaviour to 
examine the behaviour of interest - ‘attending for cervical cancer screening in the 
era of HPV testing’, and women’s intentions to be screened for cervical cancer 
screening if HPV testing is used. Specifically, this study will examine women’s 
attitudes to cervical cancer screening with HPV, subjective norms related to 
cervical cancer screening using HPV and a woman’s belief ability to control her 
attendance for cervical cancer screening (Figure 1). Information derived from the 
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proposed study can offer critical insights to clinicians and policy makers as they 
consider essential program elements for introduction of hr-HPV testing as the 
primary screen for cervical cancer in an organized North American screening 
program. 
 
 
 
 
 
CHAPTER 4: Methods 
 
Objectives: We determined intentions of Canadian women to attend 
cervical cancer screening in the era of HPV testing. We conducted secondary 
analyses using exit survey data obtained from participants who were part of a 
large clinical trial in a Canadian provincial cervical cancer screening program. 
Among women who had completed the trial, we determined intentions to attend 
for cervical cancer screening in the era of hr-HPV as a primary screen for 
cervical cancer(52).   
 
Primary Objective: Determine variables that predict intentions to undergo 
HPV testing instead of having Pap smears for cervical cancer screening 
 
Survey instrument: The survey, developed by the investigative team of 
HPV FOCAL prior to the dissertation, was based on Theory of Planned 
Behaviour (TPB) (53). For purposes of clarity, we will outline how the 
investigative team created the survey.   
 
In keeping with the principles of TPB, study items were developed from a 
thorough literature review and elicitation interviews and feedback from content 
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experts in the field.  Surveys were drafted and reviewed by a Theory of Planned 
Behaviour expert Racheal Powell) and then pilot tested on ten women in the 
target demographic.  Revisions were reviewed by principal investigators, 
investigative team and the TPB expert. A final version of the survey was piloted 
and finalized.  All items used seven point Likert scales (Appendix 1). 
 
The survey is divided into six parts (Appendix I.): 
I. Attitudes 
II. Subjective Norms 
III. Perceived Behavioural Control 
IV. Attitudes and Intentions 
V.  Self-collection for HPV 
VI. Involvement in HPV Focal study 
 
For purposes of this evaluation, findings from parts I-IV were used.  The 
primary research question is ‘What variables predict a woman’s willingness to be 
screened for cervical cancer with HPV testing instead of a Pap smear? (PI19)).  
We further examined this topic and determined how the following additional 
factors would influence willingness to undergo cervical cancer screening using 
HPV testing: 
 Cervical cancer screening using HPV testing would only be done every 4 
years instead of yearly and  
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 Cervical cancer screening using HPV testing would only be done every 4 
years and start after 25 years of age. 
 
Participants: Participants were recruited through the HPV FOCAL trial in 
British Columbia, Canada (Figure 2).  HPV-FOCAL is a randomized, controlled, 
three-armed study conducted in British Columbia(52) that has recruited 28,000 
women aged 25-65 through the province’s population based cervical cancer 
screening program. There are three trial arms: control, safety check and four 
year intervention arm.  In the control arm, liquid based cytology (LBC) was 
conducted at entry and two years, and combined LBC and high risk HPV testing 
(hr-HPV) at four years among those with initial negative results.  In the two year 
safety check arm, hr-HPV testing was conducted at entry and LBC at two years 
in those with initial negative results.  Finally, with the four year intervention arm, 
hr-HPV was conducted at entry and combined hr-HPV and LBC at four years 
among those with initial negative results. Women aged 25 to 65, registered with 
the health insurance plan for the province, who received care from participating 
family physicians (FP) for routine cervical screening were eligible.  Exclusion 
criteria were: history of histologically proven CIN2 or worse requiring treatment in 
last five years; history of histologically proven invasive cervical cancer; Pap 
smear within the preceding twelve months; no cervix; pregnant; HIV positive or 
on immunosuppressive treatments; or unwilling or unable to provide informed 
consent.    
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Recruitment: HPV FOCAL trial recruitment was completed March 2012. 
As of August 31, 2012, 28,000 women were enrolled as study participants: over 
4000 women had exited the trial. Women were invited to participate in the 
randomized trial in one of two ways.  The first approach was when women 
presented for cervical cancer screening and were deemed eligible to participate 
by their family physicians (FP). The other method of recruitment was when 
women were pre-identified as being due for screening from the provincial cervical 
cancer screening program. For the pre-identified, the FP office sent eligible 
women a study package that included invitation letter, study information 
pamphlet and appointments for their cervical screening test and also provided 
them with the opportunity to contact, or be contacted by study staff to learn more 
about the trial and decide on participation. All participants were consented by 
their FPs and asked to complete demographic and epidemiologic questionnaires 
as part of trial recruitment.  As part of their consent, women allowed researchers 
to contact them to participate in other studies (Figure 2).   
At study exit (which for this study included only women allocated to the 
two year safety check arm – Figure 2), women were mailed end of study 
questionnaires via email using fluid survey’, an online web-based survey tool that 
complies with Canadian privacy laws. Women were sent two additional 
reminders to complete the end of study survey, which included data on overall 
study participation, attitudes toward self-collection as well as attitudes about the 
future of cervical cancer screening (Appendix).  
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Sample Size: In the survey, women were asked if they intended to receive 
cervical cancer screening if HPV testing was used instead of Pap screening.  
Assuming 75% of women agreed with the statement of intention to receive hr-
HPV testing(35), with a sample size of 1000, our 95% confidence interval around 
the estimate will be ± 2.7%. 
Data Entry:  At study exit, all women who had email addresses were sent 
invitations to complete surveys.  Surveys were completed on ‘fluid surveys.  Data 
entered by participants were stored at fluid surveys and then were automatically 
populated into an Excel spreadsheet when required for analysis.  Data were then 
converted from Excel spreadsheet to SAS for analysis.
  
CHAPTER 5: Analyses 
 
Survey response rate:  Response rates were determined based on the 
standard definitions from the American Association for Public Opinion 
Research(54).  This survey is defined as a ‘list based survey’ where the 
investigators have a sampling frame of email addresses for specifically named 
persons.  As all women were participants in the HPV FOCAL trial, there are no 
women in ‘unknown eligibility’ category.  Respondents fell into the following 
categories (Figure 3): 
 
Eligible, Non-interview 
 Non-contact:  Email bounced back as incorrect 
 Refusal: Email did not bounce back, survey not completed 
 Logged on: Clicked through link, did not complete any items 
 Break off: started survey, did not complete enough information to use 
responses 
Returned questionnaire 
 Complete: survey completed 
 Partial: completed partially with sufficient information to use responses 
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Surveys responses were reviewed for completeness. In the case of duplicate 
complete surveys, the first complete survey was used and the second survey 
was discarded.  Minimum response rate (RR1) was calculated according to the 
American Association for Public Opinion Research.  RR1 is the number of 
complete surveys divided by the number of returned questionnaires plus eligible 
non-interview.  Demographic characteristics of survey non-respondents was 
available from epidemiological data from the larger clinical trial (Table 1), so we 
were able to compare non-responders and responders for mean and median 
age, education, cultural background, sexual history and smoking history.  
Continuous variables were compared with Student’s t-tests, categorical variables 
were compared with Chi-square and with Kruskal-Wallis tests to compare 
medians, as appropriate.  
Descriptive analyses of demographic characteristics of the survey 
respondents were performed, including mean and median age, marital status, 
education, sexual history, ethnicity and smoking history (Table 2). For all scale 
variables, definitions were listed in Table 3 and in the list of definitions.  
Participants’ intentions to be screened with HPV for cervical cancer (PI19>4) as 
well as overall rates of intentions to be screened every four years (IN21 >4) and 
intentions to be screened every four years after the age of 25 (IN23>4) were also 
calculated with 95% confidence intervals for descriptive analyses.  Intentions to 
be screened with HPV for cervical cancer (PI19) were examined based on five-
year age strata. 
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Overall attitude toward having an HPV test instead of Pap screening (A1) was 
assessed with four items which were summed to form an attitude scale.  
Attitudes to having an HPV test instead of Pap screening were assessed along 
with an extended screening interval (A20) and an extended screening interval 
and delayed start at the age of 25 (A22).  All attitude scales were anchored in the 
same direction, so no recoding was needed.  Item analysis using Cronbach’s α 
was conducted to determine internal consistency of scales.  If internal 
consistency was achieved for the scale (Cronbach’s alpha  >0.5), a composite 
variable was created for analyses (55).   
For direct measures of subjective norms, 3 items (SND2-SND4) were 
assessed for consistency, and summed if Cronbach’s α was >0.5.  If item 
correlation was <0.5, then subscales based on the combination of SND2, SND3 
or SND4 were created, and item correlation conducted. To create the normative 
belief score for the model for indirect norms, the belief score was multiplied by 
the score for motivation to participate in the named activity(55). For indirect 
norms, the Likert scales of 1-7 that measure normative belief (Family Physician - 
SNI5, Friends - SNI7, Spouse/Partner - SNI9, BC Cancer Agency - SNI11) were 
re-coded to a scale of -3 to +3. With this recoding, positive score indicates that 
overall, the individual experiences pressure from the individual/group named in 
the item to participate in the activity. To then create the item, the normative belief 
was multiplied by motivation to comply, thus creating 4 indirect measures 
(SNI5XSNI6, SNI7XSNI8, SNI9XSNI10, SNI11XSNI12).  The internal 
consistency of indirect subjective norm items was assessed by Cronbach’s 
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alpha.  In the case of indirect norms, if there was low internal consistency, each 
item was examined individually, and subscales based on combinations of 2 or 3 
of the indirect items were created.  This is because the indirect norm of family 
physician influence may not necessarily be correlated with that of the influence of 
a friend or spouse. Based on these analyses, either a combined scale or 
individual items was finalized for the model.   
Perceived behavioural control, consisting of 4 items (PBC15-18), was 
assessed for consistency as well.  If they had low internal consistency, we re-
examined to create subscales, likely based on self-efficacy and control.  Based 
on these evaluations, items were summed, either as two subscales or as an 
overall scale for PBC. 
In addition to the usual Theory of Planned Behaviour measures and variables, 
an additional variable of ‘contacting partners’ was created for this analysis.  One 
of the unique aspects of cervical cancer screening with HPV is that HPV is a 
communicable disease. Several studies have shown that women’s concerns 
about HPV testing are related to stigma around sexually acquired infections, 
implications of infidelity and the impact of positive HPV results on relationships 
with partners (41). Thus, there may be an expectation that sexual partners 
should be advised of an individual’s HPV status.  This expectation may influence 
a woman’s willingness to participate in cervical cancer screening, due to 
concerns about the need to disclose results of a communicable disease with 
partners. Two items assessing impact of needing to inform a partner about HPV 
status on decision to receive screening were included to determine whether the 
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communicable disease/STI element of HPV would impact on a woman’s 
willingness to have this test.  These two items (CP13; CP14) were assessed for 
internal consistency and depending on score, were summed and included as an 
independent variable in the analyses.  
Item analysis using Cronbach’s α was conducted to determine internal 
consistency of the composite scales, and scales with Cronbach’s α >0.5 were 
considered for the analysis (Table 3).  
A logistic regression model was created to predict factors associated with 
women’s intentions to be screened for cervical cancer with HPV testing. The 
focus for the multivariate model was the dependent variable ‘intention to have 
HPV testing (PI19)’.  On consultation with the provincial cancer policy leads, 
respondents were dichotomized into intend to screen for cervical cancer with 
HPV (PI19>4) and do not intend to screen for cervical cancer with HPV 
(PI19<=4).  Provincial cancer agency leads felt this dichotomization would best 
capture the characteristics of women who would intend to be screened for 
cervical cancer.  Demographic characteristics between the two groups were 
compared overall and between five year age strata, with Chi-square and 
Student’s t-test as appropriate (Table 4).  Psychological scales that achieved an 
item correlation with Cronbach’s α >0.5 were first assessed to determine if any 
were multicollinear.  We used a Pearson correlation coefficient to determine how 
strongly the psychological variables were related to each other.  If two variables 
were collinear (>0.8), based on judgment of the perceived role of the variable in 
impacting the analysis, the less influential variable was removed (Table 5).  
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Following this determination, overall scale scores and mean scores with standard 
deviations for scale results between those who intended to screen and those who 
did not (PI19) intend to be screened were calculated.  Mean results with standard 
deviations between scales that had acceptable agreement (Cronbach’s alpha 
>0.5) and not collinear were compared using Student’s t-test.   
The main research question for this proposal is What variables predict 
women’s intentions to undergo HPV testing instead of Pap testing for cervical 
cancer screening? with the model dependent variable of PI19 I would be willing 
to have an HPV test to screen for cervical cancer instead of a Pap smear. Thus, 
for the model, IN21 and IN23 were not included as they looked at the same issue 
as PI19, but with the added element of extended screening and delayed start.  
As well, the corresponding attitudes scales for IN21 and IN23, which are A20 and 
A22, were also excluded from the model.  All demographic and scale variables 
that achieved p<0.2 in the univariate and bivariate analyses, and variables that 
were believed by the investigators to be important in predicting women’s 
decisions to attend screening based on the comprehensive literature review that 
preceded questionnaire development were entered into the stepwise logistic 
regression model.   
Given the large sample size and relatively small number of variables 
considered in the analysis, we conducted a direct logistic regression analysis and 
entered all variables that achieved a p<0.2 into the model at the same time.  
Demographic data (mean age, marital status, cultural background, educational 
background, number of male sexual partners, smoking history) and psychological 
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scales [attitudes (A1), direct subjective norm (SND2-4), indirect subjective norm 
(SNI5-12), contacting partners (CP13-14), perceived behavioural control 
(PBC15-18)] where appropriate into the model. Analyses were performed using 
SAS Logistic. For the model, the model Chi-square, R squared and adjusted R 
squared as well as regression coefficients, Wald statistics, odds ratios for the 
significant variables with 95% confidence intervals were calculated to identify 
variables associated with a women’s intention to screen for cervical cancer with 
HPV.  
 
 
CHAPTER 6: Results 
 
Survey recruitment commenced May 1st, 2011 and finished September 
30th, 2011.  In May 2011, 2459 women had exited the safety arm of HPV FOCAL, 
and 2016 had email addresses. These 2016 women were all sent invitations to 
participate in the survey (Figure 3) and represent the eligible population. 1035 
were eligible but were not surveyed.  478 emails were returned or bounced back, 
so these women were ‘non-contact’.  72 replied that they did not want to 
participate, so were ‘refusals’.  191 individuals logged onto the survey, but did not 
start it, and 294 started the survey but did not complete it with sufficient 
information to use the survey. 981 returned and completed the survey.  The 
overall response rate (RR1) is 48.7% (981/2016).  
Responders and non-responders did not differ significantly in their socio-
demographic characteristics (Table 1). In particular, age, education level, cultural 
background, sexual history, smoking history and ethnicity were not different 
between survey responders and non-responders.  Survey respondents had a 
mean age of 45.1 (SD 10.1); the age range of respondents was 25 to 65 years of 
age (Table 2). Over 85% of women had more than high school education, and 
56.1% reported five or fewer sexual partners in their lives.  The majority of 
women were Caucasian, black or South Asian background; 2.4% of women were 
43 
 
aboriginal.  Six percent of women were current smokers and 36.1% had smoked 
at some time in their lives. 84.2% (95% CI 81.9; 86.5) intended to be screened 
for cervical cancer with HPV.  However, willingness to be screened with an HPV 
test instead of Pap smear decreased substantially when women were provided 
with parameters around extended intervals and a delayed start.  Willingness to 
be screened with HPV test instead of Pap smear for cervical cancer screening 
decreased from 84.2% to 54.2% (95%CI 51.1; 57.3) when women were advised 
about an extended screening interval of four years, and decreased further to 
51.4% (95%CI 48.3; 54.5) when women were advised about a delayed start of 
screening at age 25. 
Scale consistency was assessed for each construct (Table 3). Overall 
attitudes (A1), attitudes to extended screening interval (A20) and attitudes to 
extended screening interval and delayed starts (A22) all had Cronbach’s alpha of 
> 0.9, indicating excellent agreement.  The indirect subjective norms scale (SNI5-
SNI12), assessing the impact of individuals and organizations on women’s 
decisions to attend screening also had excellent agreement at >0.8.  Perceived 
behavioural control items (PBC15-18) and contacting partners items (CP13-
CP14) both showed good agreement at >0.6.  In contrast to the other scales, 
direct subjective norms had less robust agreement between the items.  SND2 
(Most people who are important to me would think that I should/should not have 
an HPV test) and SND3 (People who are important to me would expect me to 
have an HPV test to screen for cervical cancer) showed moderate agreement at 
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0.5. However, SND2/SND4 and SND3/SND4 were poorly (0.103) or not at all 
correlated (-0.045). Thus, only the SND2/3 scale was included in the analysis. 
Of 981 women who completed surveys, 826 (PI19) intended to be 
screened for cervical cancer with HPV tests instead of Pap smears 
(84.2%)(Table 4). There were no significant differences between the mean age, 
age strata, marital status, education level, sexual history, cultural background or 
smoking history of women who intend to be screened with HPV tests instead of 
Pap smears for cervical cancer (p>0.05).   Across age strata, women over the 
age of 65 had the highest rates of intention to be screened for cervical cancer 
with HPV (n= 8, 100%) and women aged 55-59 reported the lowest rate (n=116, 
81.0%).  However, there was no significant difference across all age strata for 
intention to be screened with HPV for cervical cancer (p=0.542). 
Unlike women who were willing to be screened for cervical cancer with 
HPV (PI19), there were significant differences between women who were willing 
to be screened with HPV when there was an extended interval between HPV 
tests and those who were not (IN21). Never married and divorced women were 
more likely to disagree with an extended screening interval, while common law 
and married women were more likely to agree with testing with an extended 
screening interval.  Chinese and aboriginal women were more likely to disagree 
with an extended interval.  Women with less education were more likely to 
disagree with an extended screening interval, while women with advanced 
university degree were more likely to agree with the extended interval.  When a 
delayed start to screening in addition to extended interval (IN23), education 
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levels were still significantly different between women who were willing to 
undergo screening with an HPV test compared to those who were not. 
The rest of the analyses will focus primarily on women’s overall 
willingness to be screened with HPV for cervical cancer (PI19). Univariate 
comparisons between composite scales for women who were willing (PI19>4) or 
not willing (PI19≤4) to be screened for cervical cancer with HPV tests showed 
significant differences (Table 6).  Overall, women who were willing to be 
screened with HPV tests had significantly higher attitudinal scores (A1), 
indicating their belief that HPV testing was more accurate, safe, protective and 
acceptable than Pap smears (p<0.01).  They were significantly more likely to 
report the influence of direct subjective norms (SND2-3) on their decisions, with 
the belief that most who are important to them would think they should have an 
HPV test, and would expect them to have an HPV test (P<0.01).  Women who 
intended to be screened with HPV were significantly more likely to report the 
influence of indirect subjective norms as well (SNI5-SNI12), including the 
opinions of family physicians, friends, spouse or partner and the British Columbia 
Cancer Agency as important in their decision making (p<0.01).  Women who 
were more likely to intend to be screened with HPV testing also reported 
significantly higher rates of perceived behavioural control (PBC15-18) (p<0.01).  
The role of contacting partners was also significantly different between women 
who intended to be screened with HPV and those who did not (CP13-14).  
Women who intended to be screened reported greater comfort sharing results 
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with their partners and were more likely to say that partners would be 
understanding of their HPV results (p=0.05).   
Psychological variables were reviewed for collinearity (Table 5).  No variables 
used in these analyses had p>0.8 on correlation testing, indicating that the 
variables are measuring non-collinear constructs. Based on univariate analyses 
of psychological scales, the following variables were put into the model:  
 Dependent variable: - (PI≤4 vs PI>4)  
 Independent variables: Psychological scales for attitude (A1); direct 
subjective norms (SN2-3); indirect subjective norm (SNI); perceived 
behavioural control (PBC15-18); and contacting partners (CP13-14).   
Since no demographic characteristics were significantly different in univariate 
and bivariate analyses and based on review of all the variables, no demographic 
variables were entered into the model. 
Table 7 shows the regression coefficients, Wald Chi-square statistics, 
odds ratios and 95% confidence intervals for odds ratios for variables in the 
model.  According to the Wald criterion, overall attitudes, indirect subjective 
norms and perceived behavioural control were associated with women’s 
intentions to be screened for cervical cancer with HPV instead of Pap smears.  
Odds ratios and 95% confidence intervals confirmed that positive attitudes 
regarding the value of HPV testing (OR 1.2; 95%CI 1.1, 1.3) positive indirect 
subjective norms (OR 1.02; 95% CI 1.01, 1.03) and positive behavioural control 
(OR 1.16; 95%CI 1.10, 1.23) all significantly predict women’s intentions to be 
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screened with HPV testing.  The model adjusted R-squared is 0.436, indicating 
that 43.6% of the variance in the model can be accounted for by these variables. 
 
 CHAPTER 7: Discussion 
 
Although almost entirely preventable, cervical cancer remains an 
important cause of morbidity and mortality for women worldwide (56).  In high 
income countries, such as Canada, due to extensive investments and efforts with 
cytology, colposcopy, ablative and excisional treatments have led to a reduction 
in cervical cancer morbidity and mortality in these settings (1). The need to 
explore implementation of improvements in primary and secondary prevention of 
cervical cancer should be a priority for health policy leaders and clinicians.  One 
of the newest innovations, HPV testing, has potential to contribute to improved 
outcomes since it is grounded in the relatively recent awareness of the virus’ role 
as the etiology of cervical cancer, and also has impressive attributes as a 
screening tool. However, prior to introduction of this new technology for 
screening, broader considerations should be included in deliberations regarding 
the inclusion of this new screening tool, including women’s experiences. An 
existing body of literature provides preliminary results of explorations of HPV 
testing as part of cervical cancer screening and the experience of women 
receiving HPV test results.   
Previous work indicates that in many settings, women report anxiety, 
distress, and shame when they receive positive HPV results(43;47;57). Women 
also report concern about communicating test results to sexual partners, and 
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about stigma and shame associated with having a sexually transmitted infection 
(44;45).  Although these results are illustrative, many of these findings were 
generated as part of a theoretical exercise or as part of co-testing screening with 
cytology and did not necessarily link the impact of these emotions of receiving an 
positive HPV result with impact on women’s intentions to be screened for cervical 
cancer.  It is particularly important for researchers and planners to take the next 
step to fully articulate the impact of these psychosocial concerns with the 
intended outcome of taking a screening test, to determine if a switch in 
technology could be detrimental on the uptake rates of cervical cancer screening.  
To address this, using the theoretical framework of Theory of Planned Behaviour, 
we assessed the intentions of almost 1000 Canadian women who participated in 
routine cervical cancer screening to be screened for cervical cancer with HPV-
DNA instead of Pap smears.  These data will be used towards a broader 
implementation plan for HPV based cervical cancer screening in the province of 
British Columbia.   
Surveys were emailed to all participants who had completed participation 
in a randomized controlled trial.  Not all invitees had functional email addresses, 
and not all invitees completed responses, leading to a response rate of 48.7%.  
Comparison of survey respondents and non-respondents showed that they were 
not significantly different on demographic characteristics (Table 1).  Thus, 
findings are likely to be generalizable to the population of women who were part 
of the provincial screening program and participated in a large clinical trial.  Of 
course, this study does not capture perspectives of women who did not attend for 
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cervical cancer screening.  As this population remains a key consideration for 
cervical cancer prevention, further explorations into this group are urgently 
needed, to understand both opportunities to improve uptake with novel 
approaches with HPV and also to ensure there is improved engagement.   
Survey construction, although not part of this dissertation, found that most 
of the items within scales, with the exception of direct subjective norms were 
highly consistent, and thus were reliably measuring the same construct (Table 3).  
However for two of the scales using the direct subjective norms items analyses 
found Cronbach’s alpha of <0.5.  For SND3-4, Cronbach’s alpha was 0.103, and 
for SND2-4 there was actually negative correlation (-0.045).  Scores were re-
examined to ensure that re-anchoring was conducted accurately, and findings 
were confirmed.  Thus, we are left to interpret reasons underlying poor 
correlation of some of these items. It is noteworthy that when item SND4 is 
included (‘I would feel under social pressure to have an HPV test for cervical 
cancer instead of a Pap smear’), correlation for the items was poor.  This item 
probably is not correlated with the other two items for direct subjective norms. 
Women may not believe that ‘social pressure’ will influence their behaviours, but 
if specific named individuals or groups important to them wanted them and 
expected them to be screened for cervical cancer using HPV, that would 
influence their decisions.   
One might not expect that indirect subjective norms from groups as 
divergent as family physicians, friends, spouse/partners and BC Cancer agency 
would  correlate so well at >0.8. This finding indicates the importance that women 
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place on the opinions of these groups in their decision making for cervical cancer 
screening.  There are limited available published data on attitudes of these 
groups towards screening for cervical cancer with HPV.  In one study, Fernandez 
explored men’s reactions to a partner’s HPV infection(45).  She found that men 
were concerned about uncertainty about the source of HPV infection and the 
implications of a positive HPV result for infidelity with their partners.  Ultimately 
though, men were action oriented, and wanted to understand what they could do 
to support their partners to manage infections and take control of the situation.  
Further research on the attitudes and concerns of these influential groups and 
individuals to screening for cervical cancer with HPV is needed.  As well, 
educational efforts for HPV screening should ensure that they are targeted not 
only at the women, but also at these seemingly broad groups, as they play a 
substantial impact on women’s decision around cervical cancer screening with 
HPV.  
Overall, 84.2% of women intended to have cervical cancer screening with 
HPV instead of Pap screening (Table 2).  In this analysis, no demographic 
characteristics were significantly different among women who intended to be 
screened with HPV.  In particular, age, marital status, sexual history, smoking 
history, education and cultural background were not significantly different 
between women who intended to screen for cervical cancer with HPV and those 
who do not.  There was also no difference between age strata for women who 
intended to be screened with HPV and those who did not. This is in contrast to 
several previous studies, which identified differing anxiety and concerns about 
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HPV and willingness to have HPV-based test depending on age(33;48;58), and 
cultural background(41). In particular, previous studies reported certain cultural 
groups identified concerns about the sexual nature of the infection, implications 
for fidelity and relationships and the need for disclosure(41;45). Regardless, this 
has relevance for programming.  One might expect women who have different 
educational or cultural backgrounds to be more or less reluctant to move to a 
different type of screening; particularly one with a communicable disease 
overtone, and that this ultimately could affect on willingness to be screened.  
Our data highlight a very critical trend that should be a significant 
consideration for programs moving to HPV testing for cervical cancer screening.  
Because of improved sensitivity, high negative predictive value of HPV compared 
to Pap screening as well as risk for false positive HPV tests, cervical cancer 
screening using HPV should occur every 4-5 years, not annually as has been the 
case with Pap smears(45).  However, in this study, when women are advised 
that the screening interval will be extended from one year to four years, many 
women are substantially less likely to intend to be screened with HPV. Their 
intention rates to be screened for cervical cancer with HPV drop from 84.2% to 
54.2%.  When advised that screening would not start until age 25, compared to 
current recommendations of age 18 or soon after sexual debut, their intentions to 
be screened remained low at 51.2%.  It is very apparent from these findings that 
programming must focus around the natural history of HPV, added diagnostic 
capabilities of HPV testing and its negative predictive value, in order to reassure 
women about the safety of the extended screening interval, and to ensure high 
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acceptability of this improved method of cervical cancer screening.  In addition, 
health systems are often poor at outlining the risk for over-screening.  For 
cervical cancer, overuse of HPV testing could lead to unwarranted colposcopies 
and biopsies, and perhaps create iatrogenic illnesses.  This is also an important 
message to share with women and the public. 
Further research around why women are reluctant to have an extended 
screening interval is needed.  In research on Pap smears, women were reluctant 
to have extended screening intervals; 69% of women reported that they would 
continue to receive annual screening, even if advised it was not required(38). In 
Sirovich’s survey, women believed that cost was driving intervals around 
screening, and similarly for HPV testing, women may interpret less frequent 
screening as a poorer quality screening program. There is likely a perspective 
that important precancerous lesions could be missed because of less frequent 
screening. Thus, there is a need for comprehensive education for women to 
improve their understanding about the rationales for internal change because of 
its poor sensitivity, and HPV testing has a higher sensitivity, thus decreasing the 
need for frequent screening.   Similarly, changes in age of commencement for 
screening are based on an improved understanding of the natural history cervical 
cancer, as well as an increased awareness of the potential long-term 
consequences of treatment of precancerous lesions, including preterm labour 
and low birth weight infants, not on a desire to reduce access to screening (59).  
Messaging that clearly outlines the scientific as opposed to economic 
underpinning of this decision is needed. 
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Logistic regression analyses 
Women who intend to be screened with HPV reported significantly more 
positive attitudes regarding HPV accuracy, safety, ability to protect health and 
acceptability than women who did not intend to screen.  In addition, attitudes of 
specific groups and behavioural control emerged as significant predictors of an 
intention to be screened with HPV. This indicates that substantial efforts should 
be invested in ensuring women are aware of the diagnostic attributes of HPV 
testing, as this is a key element for women to understand the safety, accuracy 
and acceptability of HPV testing and thus intending to receive HPV testing.  
Similarly, education and awareness in particular groups who are influential for 
women (friends, family physicians, spouses and BC Cancer Agency) is important 
for planners, as these groups play a key role in women’s decision about 
screening with HPV.  Finally, women need to feel that they can obtain HPV 
testing, should they desire it, and this is another significant predictor of intending 
to be screened with HPV.  
 
 
CHAPTER 8: Study Limitations 
 
Although this research provides important new information for program 
planning for HPV screening, there are limitations, which are related to limitations 
in the survey design and implementation as well as with the sample of women 
who completed survey.  
Although the survey was designed with careful attention to the 
recommended methods for Theory of Planned Behaviour (51), it is possible that 
the survey did not assess appropriate variables relevant for predicting 
participation in cervical cancer and the factors that were important for intention to 
be screened for cervical cancer with HPV.  Variables selected for analyses were 
based on initial consultation with experts, comprehensive literature reviews and 
pilot testing with eligible women.  It is possible that some factors of importance 
were missed in this overview, and as such, some key elements in decision 
making for women were not included.  One emerging theme that was not 
explored was the need for explicit consent to be screened with HPV for cervical 
cancer.  Women have identified an expectation that clinicians’ will make sure 
they are aware that they are receiving an HPV test for cervical cancer screening 
(34;39;46).  Although this issue potentially could be embedded in the items on 
perceived behavioural control (i.e. the concept of consent is embedded in 
control), perhaps it would 
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have been helpful to explicitly examine this in the survey.   In addition, some 
women in the pilot group found the rigid structure of TPB survey awkward and 
this may have affected their response patterns. 
Although this study assessed women’s intentions to be screened for 
cervical cancer with HPV using a very large sample, some limitations should be 
considered as we apply findings to program decisions.  Ultimately, to improve 
cervical cancer screening, programs should recruit all women in a population to 
engage in cervical cancer screening.  As this study only surveyed women who 
had family physicians, were already engaged in cervical cancer screening and 
were part of a large randomized trial, the findings may not accurately 
characterize the concerns and experiences of women who have not been 
screened for cervical cancer.  As the trial sample size is substantial (28,000) and 
women are recruited from the province, there is less concern about its 
generalizability to the sample of women who attend for screening.  However, this 
study did not survey any women who do not have regular care providers, nor 
women who do not attend for screening. Thus, we may not be able to inform the 
program about how to improve participation in women who have never been 
screened for cervical cancer.  This is particularly important, because HPV offers 
some innovative methods for screening, including self collection(60;61) and when 
used as part of screening programs can improve uptake in women who don’t 
attend for cervical cancer screening(62;63). Future research should attempt to 
explore the attitudes of women who have not attended for screening, to ensure 
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that the use of HPV screening will not negatively impact on any efforts for 
engagement into screening. 
In addition, although over 90% of women have had Pap smears at some 
time in their lives, we only surveyed women who had completed participation in a 
randomized trial.  It is possible that the sample may be more educated that the 
population as a whole, thus we may potentially miss some specific concerns of 
women who are less educated.  Only women with electronic mail addresses were 
eligible to complete surveys.  Not all women who started the survey completed it.  
All of these may affect the generalizability of survey findings. 
 CHAPTER 9: Plan for change 
 
Pap screening has been described as a rite of passage, and any proposed 
changes to this long established screening program will require careful 
deliberation and planning.  Introduction of primary HPV testing would be a 
paradigm shift in the delivery of this long established screening program, since 
use of HPV testing would lead to changes in both the frequency of testing and 
the consequences of positive test results. Currently, the British Columbia Cancer 
Agency recommends that women be screened for three years annually using 
cytology, and then every two years if the initial three screenings are negative. 
Even with these recommendations, many women still choose to attend for 
screening every year. Because hr-HPV testing offers improved sensitivity for 
detecting precancerous lesions, a negative test offers greater assurance to the 
clinician and screening participant that they are not at risk for developing cervical 
cancer in the near future.  Recent reviews by Dillner (14) have proposed that 
screening intervals for hr-HPV negative women could be extended to five years, 
yet still offer effective and safe screening for cervical cancer precursors. If hr-
HPV testing were offered in British Columbia, women who have been 
accustomed to receiving annual screening would be advised and possibly limited 
to cervical cancer screening every five years.  Findings from these analyses have 
identified in a large, representative sample of women who have participated in 
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cervical cancer screening, women’s key concerns in the shifting paradigm of 
cervical cancer screening, and in particular what factors are associated with an 
intention to be screened with HPV cervical cancer screening.   
 
Leadership Models 
To implement a large program change, relying on well-established models 
for change will help to provide a road map to ensure a successful evolution in the 
screening program. There are a wide variety of models of leadership theory in 
public health that could be used to help guide this change.   Yukl (64) defines 
leadership as a process where ‘intentional influence is exerted over other people 
to guide, structure and facilitate activities and relationships in a group or 
organization.’  To lead change, Yukl focuses on a comprehensive understanding 
to detail the variety of reasons for resisting change which may include some of 
the following - lack of trust, belief change is not necessary, belief that change is 
not feasible, economic threats, relative high costs, fear of personal failure, loss of 
status and power, threat to values and ideals, and resentment to interference.  
He then outlines the characteristics and nature of the organizational culture, and 
then explores how leaders can act to change them.  In his outlines for change, he 
focuses on leadership behaviours to create a vision, which includes broad 
consultation, identifying strategic objectives with wide appeal, identifying relevant 
elements in the old structure, clear linking to core competencies and evaluation 
of the vision.   To implement change, Yukl outlines guidelines that align very well 
with Kotter’s eight step model(65).  This includes 1) need for a sense of urgency, 
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2) Form a powerful guiding coalition, 3) create a vision 4) communication of a 
clear vision of the benefits, 5) identify both key supporters and resisters, building 
a broad coalition for change, filling key positions with change agents and 
empower them to act, 6) create a dramatic change to signal the shift in work and 
then work on the ground to help people deal with the change.  He then identifies 
the need for 7) early successes and 8) monitoring and communicating progress. 
Other theories offer a variety of different perspectives on leadership 
change, include Meadow’s system views with an exploration of system 
archetypes and implementing change based on the leverage points of a 
system(66).  Johnson-Cramer (67) proposes managing change by defining 
system networks, identifying dominant beliefs and values in the system and then 
focusing change at the correct relational dimensions of the system network.  An 
appreciative inquiry approach builds on organizational strengths, and by 
harnessing the previous successes of an entity, change can be catalyzed by 
championing the key aspects of success(68).   
All of these previously mentioned approaches have proven track records 
for successful implementation of change, but Kotter’s eight step model for 
change is perhaps one of the most widely known models for change, and is 
highly applicable to this situation, due to its practicality and simplicity (65). It 
takes a step away from theory, and is a practice-based approach, grounded in 
action and engagement, and prescribes a step-by-step approach for creating 
success. By aligning with Kotter’s strategic approach, we can expect a high 
likelihood of success in our drive for change.  This chapter of the dissertation will 
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further discuss the application of leadership theory and practices to successful 
implementation of a program change. Each step is described in relation to the 
model, and then steps that I will take to implement this substantial change in 
screening. 
Create a sense of urgency:  There is a need for government, clinicians 
and the public to understand the current limitations of cytology as the basis for 
cervical cancer screening, the risks and harms of over-screening, and the 
increasing evidence of the advantages of HPV testing compared to cytology.  In 
particular, women and clinicians should understand that even with the increased 
intervals between screening and delayed start, HPV testing offers superior 
capability for detecting precancerous lesions. There is also a need for clear 
understanding that inappropriate use of HPV screening (i.e. using it in women 
under the age of 25 or using it too frequently) poses risks for women to be 
harmed by over-investigation of innocuous lesions which can lead to reproductive 
consequences in their future (59).  
Recommended action: I will identify the key opinion leaders on cervical 
cancer screening and cancer prevention from the BC Cancer Agency. As well, I 
will identify respected leaders in women’s health and public health from 
institutions such as the clinical practice leads from BC Women’s Hospital and the 
Office of the Provincial Health Officer.  These individuals will be educated and 
engaged regarding cervical cancer screening with HPV, and then named as key 
spokespeople for cervical cancer prevention for the province. I will prepare 
standard messaging around HPV testing, so that all spokespeople have a shared 
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set of messages.  The key messages will include findings from international trials 
on the improved detection of cervical cancer with HPV, issues with the current 
technology used as well as findings from this analysis, that show that the majority 
of women intend to be screened for cervical cancer with HPV. 
With any new development or research publications in the field of HPV 
testing, press releases will be sent to local and provincial media, and these 
spokespersons will be available to describe the significance of these findings, 
and advocate for HPV testing, and articulate the urgent need to evolve to this 
type of screening. I will also use any presentation at international conferences as 
an opportunity for local media to highlight new findings and results from 
international trials on HPV testing.  Also, any publications on HPV testing from 
provincial scientists and clinicians will have press releases attached to them, so 
we can also capitalize on those opportunities.   
I will also seek opportunities at key professional conferences, such as the 
BC College of Family Physicians meeting, BC Pediatric Society meeting, BC 
Obstetricians and Gynecologists Society to present information on HPV testing 
and cervical cancer screening.  Finally, I will arrange for these opinion leaders to 
present briefing notes and presentations for the Ministry of Health and the 
relevant Health Authorities, so that the funders will be aware of the need to 
move, and can be part of making this testing available.  The expectation is that 
these efforts will create a sense of the need for HPV testing for the province, 
which will then lead to political and ultimately public support and expectation that 
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this type of testing is state of the art, and will be made available for all women in 
the province.  
 Form a powerful coalition:  Provincial leaders in cancer prevention, 
women’s health, sexual health and communicable disease prevention need to 
align in the province in a formal effort to support and engage around the use of 
HPV testing for cervical cancer screening.  These leaders need to have a shared 
voice in the benefits of HPV testing. 
Recommended action: As part of the implementation of the HPV vaccine 
program in the province, I helped to create this broad coalition, which included 
BC Cancer Agency, BC Centre for Disease Control, BC Women’s Hospital, BC 
Children’s Hospital and the Office of the Provincial Health Officer. I will now re-
engage this group of leaders to ensure they are informed of the shifting paradigm 
for cervical cancer screening, and to provide guidance for the province as it 
moves to this new paradigm of screening. Specifically, results from provincial 
studies, such as HPV FOCAL, recommendations from other jurisdictions such as 
Ontario and Quebec (29), as well as international recommendations from the 
European gynaecological society will be shared with this coalition (69).  Findings 
from this study will also demonstrate the support of women in moving to this 
screening paradigm. In addition, key opinion leaders, such as gyne-oncologists, 
gynecologists, infectious disease specialists, family physicians, pathologists and 
other clinical specialists need to be part of the coalition for change.  As described 
above, I plan to engage these individuals through opinion leaders in the province, 
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to ensure they can articulate the rationale for the change to HPV screening, as 
well as the benefits for individuals in the province. 
Create a vision for change: Provincial leaders in the fields (BC Cancer 
Agency, BC Centre for Disease Control, BC Women’s Hospital and leading 
clinicians) need to articulate the benefits of this new screening program and 
formally adopt recommendations around HPV testing in the province. For 
example, creating a clear statement such as ‘No woman in British Columbia 
developing cervical cancer’ would be a vision that most could rally around and 
support.  
Recommended action:  As a publicly funded health system, vision for 
changes need to include the support of the Ministry of Health, which provides 
funding, as well as the BCCA, who will deliver and manage this service.  Using 
the coalition, I will create a business case to support the move to HPV testing.  
This will likely require the support of a consultant, and needs to include a 
scientific rationale, as well as costing estimates, cost benefit analyses, 
implications for colposcopy and for surgical services.  This document will also 
articulate how the new paradigm of screening will be implemented, and outline 
impacts on service provision at the local level.  It will also include the risk for the 
province of not moving to HPV testing, which will include litigation for failing to 
identify precancerous lesions with cytology.  The business case will also identify 
that women support this move, but that there needs to be substantial education 
to ensure women have positive attitudes around the safety, accuracy and 
acceptability of HPV testing. We will also be able to confirm that women are not 
65 
 
concerned about the communicable disease aspect of the testing modality, but 
can also demonstrate due diligence by flagging that the extended screening 
interval and delayed start is a concern for women. This will reassure the Ministry 
that the coalition has thought broadly about the impacts of this change.  The 
critical aspect to this document is that it will be endorsed by the broad coalition, 
to ensure that the Ministry feels confident to move forward in the recommended 
direction. 
Communicate the vision: With a shared, clear vision and concise actions, 
communication plans for their stakeholders and for the public can then follow.  As 
the public relies substantially on their personal providers for health advice, it 
would be particularly important for the coalition to communicate the vision to the 
primary care providers, and ultimately for the primary care providers, with the 
support of the coalition to connect with their patients.  The public also is 
increasingly proactive in seeking their own health information, and so use of 
reputable provincial websites, will be the foundation for any public messaging for 
a change in cervical cancer screening policy.  Links with widely used and popular 
social media sites will also be part of an approved dissemination process.  
Consistent content, messaging and look that incorporates some of the key 
results from this research would be an important platform. The findings from this 
study will be particularly informative in this part of the plan for change, as we are 
informed as to the key areas of concern for women with this shifting paradigm, 
and can ensure any messaging specifically and accurately addresses those 
concerns. 
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Recommended action:  Using similar methods as earlier described for 
establishing a sense of urgency, I will utilize local media, press releases, key 
opinion leaders, to ensure broad sensitization for the public and practitioners.  
However, I will now ensure the message is further nuanced, from the need to 
move to HPV testing, to one where the focus is on the benefits of HPV testing for 
the province.  Key elements of these messages will include: evidence based 
practice; information from HPV FOCAL from BC; British Columbia leading the 
way in offering cutting edge and optimal technology; opportunity to decrease 
health care costs; opportunity to decrease over-screening; opportunity to prevent 
cancer.   
Consistent content will be developed to be posted and communicated 
broadly on key provincial agency websites, including BC Cancer Agency, BC 
Centre for Disease Control, BC Women’s Hospital. I would also recommend the 
use of popular social media sites, such as Facebook to share information as well. 
In designing the messaging for the public, I will rely the findings from this study to 
direct the content of our messaging and to ensure we address some of the key 
concerns for women.  As attitudes to HPV testing were most strongly associated 
with an intention to be screened with HPV for cervical cancer in our logistic 
regression analysis, I plan to communicate the accuracy, safety, and the ability of 
HPV to protect women’s health as the foundation for any messaging.  I will also 
identify for women that their practitioners and BC Cancer Agency strongly 
endorse this approach to cervical cancer testing, and recommend that women be 
screened with HPV for cervical cancer. In addition, because women identified the 
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need for ease and control for HPV testing as another predictor of intention to be 
screened with HPV for cervical cancer, I will communicate that HPV will be 
funded as part of the provincial screening program and can be easily accessed 
through their family physicians.  Although concerns about contacting partners did 
not achieve significance in the logistic regression modeling, I will also ensure that 
messaging reassures women that HPV is a highly prevalent virus and infections 
are common for all women.  Because our data demonstrates a substantial 
reduction in intention to be screened with HPV when screening intervals are 
extended, I will include information on the improved ability of HPV to detect 
relevant precancerous lesions compared to cytology.  Women need to be aware 
of the risks of overscreening, and that inappropriate use of HPV testing could 
actually result in treatment and potential reproductive health consequences.  I will 
also communicate the reason for the extended screening, and focus on the 
higher negative predictive value, and thus the need for fewer screens over a 
lifetime.   
Remove obstacles:  Obstacles for HPV testing can be both from the 
communication perspective and from the administrative perspective.  Some 
individuals and groups will express concern about this shift.  In particular, based 
on the pilot results and initial reactions to HPV screening in other settings, 
advocacy groups may be concerned that women are being ‘limited’ in accessing 
their health care, because of the delayed start and extended interval.  In Canada, 
with a universal health care system, any perception of ‘reduced access to care’ is 
viewed as a change driven by budgetary and not clinical elements.  Key opinion 
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leaders who understand both the improved accuracy of HPV testing as well as 
the potential harm with over screening will need to be quickly responsive to 
concerns in the media and in the public.   
Ensuring that clinicians can easily and seamlessly access HPV testing 
and their results will be fundamental aspect to the success of the new screening 
program.  Fortunately, in BC, we have been offering over 20,000 HPV tests per 
year as part of the HPV FOCAL trial at the centralized public health laboratory, 
so it will be primarily an issue of scaling up. In addition, there are strategic 
implementation approaches, such as starting with older women that can ease in 
the system of HPV testing. 
Recommended action: I will work to identify any high profile skeptics and 
bring them into the coalition.  These individuals will be able to articulate their 
concerns to the opinion leaders in the province, and can have their issues 
scientifically addressed.  In many cases, individuals with concerns about a 
change need assurances that the coalition and leaders are aware of their 
concerns, believe they are serious, have reviewed them in detail and are taking 
steps around monitoring and evaluation of the new change.  As well, skeptics 
often bring forward previously unidentified concerns and issues which will assist 
in deployment.  By proactively engaging with them, critical issues can be flagged 
and solutions reached prior to implementation.  Often, with careful stewardship, 
skeptics can often become leading advocates of the change. 
The other major obstacle for implementation will be costs for this new 
testing paradigm.  I will address this by leading the coalition to prepare a 
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comprehensive business case for the province.  This will include rationale for the 
move, cost effectiveness and cost benefits of HPV testing, as well risks for the 
province if we remain with cytology. These risks broadly include over screening, 
as well as missed cases of cancer. 
In other settings, laboratory infrastructure could be a substantial issue, but 
given that the HPV FOCAL trial has been implemented for over four years, with 
routine HPV testing with liquid-based cytology, many of the key elements are 
already in place, and simply require scaling up. 
Create short-term wins: Early on in the screening, the team will need to 
search for the ‘medical narrative’ to highlight cases of cancer that have been 
prevented using HPV screening. In addition, women who have required 
enhanced screening with Pap smears as a result of false positive cytology may 
also be able to reduce their frequency of screening with the use of HPV testing.  
Cases such as these can be highlighted and communicated, to better provide 
concrete examples of the benefits of HPV screening for women in the province.  
Additional advantages of HPV testing, such as prevention of adenocarcinoma 
should be captured and highlighted broadly. 
Recommended action: I will work with the BC Cancer Agency to identify 
practitioners and patients who have directly benefited from this switch to HPV 
testing.  I will identify women who had previously required more intensive 
screening and who can now reduce their screening frequency, and assuming 
their willingness to participate, will ask them to share their story with the media to 
effectively create the medical narrative.  I will also identify women who were ‘Pap 
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negative’ but are HPV positive who received definitive treatment. This will be 
important, to demonstrate the cancer prevention benefits of HPV testing.  With 
these success stories, the Ministry of Health will be invited to be part of the ‘good 
news’.  Similarly, local opinion leaders will be invited to provide success stories 
with the new screening paradigm.  In particular, some of the issues raised by 
women in this study, such as the extended intervals, will be highlighted as 
opportunities for both the women and the health care system. 
Build on the change: Building on examples from above, the guiding 
coalition can offer expanded guidance on how to further implement the use of 
HPV testing to streamline and improve cervical cancer detection.  This may 
include use of self collected specimens in women who do not attend for 
screening, or better defining the age to stop screening for cervical cancer. 
Recommended action:  To build on change, I will need to ensure that the 
coalition continues to meet and monitor the impact of the implementation of this 
change.  By doing so, we can identify both ongoing issues and proactively 
address and resolve them.  In addition, I will prioritize new opportunities with 
HPV testing, and work to implement small pilot projects to explore new forefronts. 
Anchor changes in the corporate culture: Finally, lessons learned from 
changing this well established screening program will be highly relevant to all of 
the agencies involved.  These lessons will also have substantial international 
importance. A careful examination of how the change was managed, impacts of 
the change on screening and treatment rates, and also how the change could 
have been improved will be crucial.  Any ongoing areas of challenge in the 
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acceptability of HPV screening will be important to analyze and steps taken to 
mitigate these remaining issues. 
Recommended action:  Anchoring the changes in the corporate culture 
will be central role for the guiding coalition.  I will continue to lead this group on 
an ongoing basis to monitor the impact of the changes, through routine 
surveillance and evaluation processes.  The coalition will also need to make a 
commitment to peer reviewed publications as well as publicly available reports, in 
order to ensure communication of its successes as well as lessons learned.  
Planned and routine engagement with local media to share the successes will be 
an ongoing priority of the guiding coalition as well. 
 
Required resources 
A comprehensive and thoughtful plan for change will require a committed 
champion as well as resources in order to effectively implement the change.  
Resources to pay for HPV testing and for clinicians will be a key element in any 
business case and analysis for the Ministry of Health, and the program will not 
move forward with this type of commitment from the Ministry.  However, the 
leadership of this change effort will need to engage opinion leaders across 
provincial agencies such as the BC Cancer Agency, BC Centre for Disease 
Control, BC Women’s Hospital, Provincial health services authority laboratories 
and the Vaccine Evaluation Centre.  As these agencies are mandated to offer 
provincial leadership, expertise and consultation to the Ministry of Health, no 
additional funds would be allocated to lead and participate in the process of this 
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transition.  Clinicians and scientists would be expected, as part of their leadership 
roles in the province, to contribute to the effort of change.
 CHAPTER 10: CONCLUDING REMARKS 
 
Cervical cancer screening remains one of the greatest successes of 
modern medicine, but is at a critical juncture.  Changing this rite of passage 
requires extensive planning and evaluation, but optimizing this screening 
paradigm is urgently required for the women and for our society, to more 
effectively diganose pre-cancerous lesions, more efficiently use our scarce health 
care resources and to limit unncessary procedures for women.  This dissertation 
explores one focused aspect of this change, and examines the acceptability and 
potential impact of this change on the individuals at the centre of the screening 
program.  Findings from this study will be of substantial importantce to British 
Columbia, and in other settings with established cervical cancer screening 
programs, to ensure that the critical participants in screening, the women, are 
able to feel confident in any changes made. 
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FIGURES 
 
 
 
 
Figure 1. Theory of Planned Behaviour (51) 
 
 
 
 
 
 
 
 
  
Figure 2.   HPV FOCAL – Clinical Trial flow chart (52) 
 
*Survey participants all recruited from 2- year safety check arm
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Figure 3. Study Flowchart and participant disposition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment May 1st 2011-September 30th 2011 
HPV FOCAL participants completed study: n=2459 
HPV FOCAL participants eligible (email address): n=2016 
Eligible, Non interview 
n=1035 
Logged on 
n=191
Refusal 
n= 72 
Returned Questionnaire 
n=981 
Non-contact 
n=478 
Complete 
n=981
Break off 
n=294
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Tables 
  
 
Table 1. Comparison of demographic characteristics of survey respondents and 
survey non-respondents* 
 
Characteristic Group 
Overall
N (%)
Respondent
N (%)
Non-
Respondent
N (%)
P-
Value
  
Overall   2016 981 1035
Age, 
Recruitment 
Mean (SD) 45.1(10.1) 45.0(10.0) 45.3(10.2) 0.5248
 Median (IQR) † 45.0
(38.0, 53.0)
 45.0 
(38.0,53.) 
46.0
(37.0,  53.0)
 
Education Missing 130 130 0.2330
 <High School 31(1.6%) 11(1.1%) 20(2.2%)
 High School 
(Complete) 
248(13.1%) 122(12.4%) 126(13.9%)
 Trade/College/
University 
(Incomplete) 
692(36.7%) 356(36.3%) 336(37.1%)
 University 
graduate 
584(31.0%) 311(31.7%) 273(30.2%)
 University 
Advanced 
Degree 
331(17.6%) 181(18.5%) 150(16.6%)
Sexual 
Partners - Ever 
Missing 151 151 0.8514
 0 4(0.2%) 1(0.1%) 3(0.3%)
 1 362(19.4%) 185(18.9%) 177(20.0%)
 2 to 5 693(37.2%) 364(37.1%) 329(37.2%)
 6 to 10 408(21.9%) 221(22.5%) 187(21.2%)
 11 to 50 376(20.2%) 198(20.2%) 178(20.1%)
 >50 22(1.2%) 12(1.2%) 10(1.1%)
Cultural 
background 
Missing 128 128 0.2879
 Chinese 175(9.3%) 81(8.3%) 94(10.4%)
 Aboriginal 46(2.4%) 24(2.4%) 22(2.4%)
 Caucasian 
and other 
1667(88.3%) 876(89.3%) 791(87.2%)
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Characteristic Group 
Overall
N (%)
Respondent
N (%)
Non-
Respondent
N (%)
P-
Value
Smoke, Now Missing 188 188 0.1908
 No 1707(93.4%) 923(94.1%) 784(92.6%)
 Yes 121(6.6%) 58(5.9%) 63(7.4%)
Smoke, Ever Missing 184 184 0.4382
 No  1156(63.1%) 627(63.9%) 529(62.2%)
 Yes 676(36.9%) 354(36.1%) 322(37.8%)
*Pearson’s Chi Square 
Student’s t-test 
†Kruskal-Wallis 
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Table 2.  Demographic characteristics of survey respondents 
 
Variable Group 
Overall 
N (%)
Overall  981 (100.0)
Age, Recruitment Mean age (SD) 45.1(10.1)
 Median age (IQR)  45.0(38.0, 53.0)
Marital Status Divorced 108(11.0%)
  Common Law/Married 689(70.2%)
  Never Married 112(11.4%)
  Widowed 7(0.7%)
  Did not Answer/Missing 65(6.6%)
Education <High School 11(1.1%)
  High School (Complete) 122(12.4%)
  Trade/College/University(Incomplete) 356(36.3%)
  University graduate 311(31.7%)
  University Advanced Degree 181(18.5%)
Education: Combined High School or Less 133(13.6%)
  More than High school 848(86.4%)
Sexual Partners – Ever 0 1(0.1%)
  1 185(18.9%)
  2 to 5 364(37.1%)
  6 to 10 221(22.5%)
  11 to 50 198(20.2%)
  >50 12(1.2%)
Cultural background Chinese 81(8.3%)
  Aboriginal 24(2.4%)
  Caucasian and other 876(89.3%)
Smoke, Ever No 627(63.9%)
  Yes  354(36.1%)
Intend to screen with HPV  PI19>4  826 (84.2%)
Intend to screen with HPV 
every four years  IN21 >4 532 (54.2%)
Intend to screen with HPV 
every four years starting at 25 
years  IN23>4 504 (51.4%)
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 Table 3. Characteristics of scale items: Correlation by Cronbach’s alpha 
 
Screening Concepts: Composite variables Scale Item Cronbach’s 
alpha
Attitudes  A1 0.917
Attitudes for HPV testing every four years A20 0.964
Attitudes for HPV testing every four years and 
after age of 25 
A22 0.968
Subjective Norms: Direct SND2-SND4  
Subjective Norms: Direct 2/3  SND2-SND3 0.478
Subjective Norms: Direct 2/4 SND2 and 
SND4 -0.045
Subjective Norms: Direct 3/4 SND3-SND4 0.103
Subjective Norms: Indirect SNI5-SNI12 0.823
Contacting Partners CP13-CP14 0.633
Perceived Behavioural Control PBC15-
PBC18 0.626
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Table 4. Univariate and bivariate comparisons between demographic 
characteristics of women who intend and do not intent to receive cervical cancer 
screening with HPV  
 
Variable Group 
Intend to 
screen with 
HPV; 
PI19 >4 
N (%) 
Do not 
intend to 
screen 
with HPV; 
PI19<=4 
N (%) 
P-
Value
     
Overall  826(84.2%) 155(15.8%) 0 
Age Mean (Standard deviation) 44.9 (10.1) 45.1 (9.2) 0.8874
Age 25-29 67 (83.8) 13 (16.3) 0.542
 30-34 65 (86.7) 10 (86.7)  
 35-39 124 (86.1) 20 (13.9)  
 40-44 151 (82.5) 32 (17.5)  
 45-49 142 (84.0) 27 (16.0)  
 50-54 111 (81.6) 25 (18.4)  
 55-59 94 (81.0) 22 (19.0)  
 60-64 64 (91.4) 6 (8.6)  
 65+ 8 (100) 0 (0)  
Marital 
Status Divorced 88(10.7%) 20(12.9%) 0.7427
  Common Law/Married 581(70.3%) 108(69.7%)   
  Never Married 95(11.5%) 17(11.0%)   
  Widowed 7(0.8%)     
  Did not Answer/Missing 55(6.7%) 10(6.5%)   
Education <High School 9(1.1%) 2(1.3%) 0.6839
  High School (Complete) 105(12.7%) 17(11.0%)   
  Trade/College/University(Incomplete) 292(35.4%) 64(41.3%)   
  University graduate 264(32.0%) 47(30.3%)   
  University Advanced Degree 156(18.9%) 25(16.1%)   
Education: 
Combined  High School or Less 114(13.8%) 19(12.3%) 0.6065
  More than High school 712(86.2%) 136(87.7%)   
Sexual 
Partners - 
Ever 0 1(0.1%)   0.6869
  1 155(18.8%) 30(19.4%)   
  2 to 5 315(38.1%) 49(31.6%)   
  6 to 10 180(21.8%) 41(26.5%)   
  11 to 50 165(20.0%) 33(21.3%)   
  >50 10(1.2%) 2(1.3%)   
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Cultural 
background Chinese 71(8.6%) 10(6.5%) 0.3236
  Aboriginal 18(2.2%) 6(3.9%)   
  Caucasian and other 737(89.2%) 139(89.7%)   
Smoke, 
Ever No 527(63.8%) 100(64.5%) 0.865
  Yes  299(36.2%) 55(35.5%)   
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         Table 5. Assessment of scale collinearity  
 
Variable 
Age at 
recruitment A1 A20 A22
SND2-
3 SNI
PBC15-
18 
CP13-
14
Age at 
recruitment 1.00 0.09 0.11 0.13 0.11 0.07 0.05 -0.04
A1   1.00 0.39 0.36 0.58 0.56 0.45 0.04
A20    1.00 0.80 0.30 0.37 0.27 0.06
A22     1.00 0.27 0.33 0.21 0.07
SND2-3      1.00 0.59 0.38 0.04
SNI       1.00 0.47 0.16
PBC 15-18        1.00 0.13
CP13-14          1.00
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Table 6. Comparison of scale results between women intending to undergo HPV 
testing instead of Pap smear for cervical cancer screening  
 
Psychological scales 
Mean 
score 
Overall 
(SD)
Intend to 
screen 
(PI19 >4)
Mean (SD)
Do not intend 
to screen 
(PI19<=4) 
Mean (SD) 
P 
Value*
 
Attitudes to HPV testing (A1) 25.7 (3.7) 26.5 (2.4)
 
21.2 (5.7) <.0001
Subjective norms, Direct 
(SND2-3) 
11.0 (2.6) 11.4 (2.3) 8.8 (2.6) <.0001
Subjective norms, Indirect 
(SNI5-12) 
34.8 
(31.9)
40.7 (28.9) 3.3 (28.8) <.0001
Perceived Behavioural Control 
(PBC 15-18) 
 
23.4 (4.1) 24.1 (3.7) 19.6 (4.1) <.0001
Contacting Partners  
(CP13-14) 
12.6 (2.2) 12.7 (2.2) 12.2 (2.6) 0.0555
 
*Student’s t-test
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Table 7. Multivariate Logistic Regression Analysis 
 
 
  
 
 
Variable Name Regression 
co-efficient 
Wald Chi-
square 
statistic 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
Attitudes to HPV (A1) 
 
0.2024 
 
43.157 
 
1.224 
 
1.153; 
1.301  
Indirect subjective norms (SNI5-12) 0.0222 27.018 1.022 1.014; 
1.031 
Perceived behavioural control  
(PBC 15-18) 
0.1471 26.259 1.158 1.095; 
1.225 
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Table 8. Leadership Models 
 
Leadership 
Model 
Definition/ 
Focus 
Foundation  Action 
Yukl (64) Intentional 
influence is 
exerted other 
people to guide, 
structure and 
facilitate activities 
in a group or 
organization 
Identify reasons for existing 
change: 
Lack of trust 
Change is not necessary 
Change is not feasible 
Economic threats 
Relative high costs 
Personal failure 
Loss of status or power 
Threats to values and ideals 
Resentment of interference 
Create a vision 
from broad 
consultation 
Identify strategic 
objectives with 
wide appeal 
Link to core 
competencies 
Evaluate vision 
Kotter (65) Leadership defines 
what the future 
should look like, 
aligns people with 
that vision, and 
inspires them to 
make it happen 
despite the 
obstacles 
Create a sense of urgency 
Form powerful coalition 
Create a vision for 
change 
Communicate the 
vision 
Remove obstacles 
Create short term 
wins 
Build on the 
change 
Anchor changes in 
the corporate 
culture 
Meadows 
(66) 
Leverage points 
are places within a 
complex system 
where a small shift 
in one thing can 
produce big 
changes in 
everything  
Places to intervene in a system: 
 Constants, parameters, numbers 
 Regulating negative feedback loops 
 Driving positive feedback loops 
 Material flows and nodes of material 
intersection 
 Information flows 
 Rules of the systems 
 Distribution of power over the rules of the 
system 
 Goals of the system 
Mindset or paradigm out of which the system 
arises 
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Johnson-
Cramer (67) 
Organizational 
network analysis is 
a set of analytical 
tools to assess 
interaction 
patterns, which 
can affect change 
via power, 
diffusion of ideas 
and formation and 
maintenance of 
belief structures 
Working through key culture 
carriers 
Uncover cultural brokers and 
marginalized perspectives 
Diagnose how culture 
fragments networks 
Assess diffusion of 
prescribed values, norms and 
practices 
Identify dominant beliefs and 
values 
Design 
intervention 
targeting the right 
relational 
dimensions 
Boje (68) Appreciating what 
already works 
Discovery: appreciating what 
is 
Dreaming: Imaging what 
might be 
Designing: determining what 
should be 
Delivering/Destiny: 
Creating the future
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Appendix 1 
 
Study Questionnaire 
 
Thanks for participating in the HPV FOCAL trial.  We invite you to complete this 
on-line survey in order to help us to plan for the future of cervical cancer 
screening in British Columbia.  We are conducting this survey to help understand 
women’s attitudes to screening for cervical cancer with HPV testing instead of 
Pap smears.  This survey will take you about 10 minutes to complete, and all 
who complete the survey are eligible to win one of 5 iPODs. Please remember, 
your name, or any other personal identifiers are not linked with the questionnaire 
responses in any way. 
 
Here is some background information for you to consider before you complete 
this survey. 
 
The human papillomavirus (HPV) is a common virus that can infect the cervix 
(part of a woman’s womb). It is now known to be the cause of cervical cancer. 
Women develop HPV infections in the cervix after having sexual activity with a 
partner who is infected with HPV. However, HPV is so common that over 75% of 
sexually-active women will have an HPV infection of their cervix sometime during 
their life. Most women who find out they have an HPV infection in the cervix after 
the age of 30, were infected with HPV years before. Over 90% of women who 
are infected with HPV in the cervix get rid of the infection naturally. It is only 
women who have longstanding infections with certain types of HPV who may be 
at risk for developing cervical cancer. Women may not have known it in the past, 
but it is these same HPV infections that are the most common reason for 
abnormal Pap smears.  
 
Right now in BC, women start cervical cancer screening once they become 
sexually active. We now know that testing for HPV infections in the cervix is more 
accurate than the Pap smear  for predicting whether or not a woman will develop 
cervical cancer. 
 
I. Attitudes 
 
 
A1. Having an HPV test to screen for cervical cancer instead of a Pap smear 
would be: 
 
Accurate 1 2 3 4 5 6 7 Inaccurate 
Safe  1 2 3 4 5 6 7 Unsafe 
Protect my health 1 2 3 4 5 6 7 Harm my health 
Acceptable  1 2 3 4 5 6 7 Unacceptable 
 
II. Subjective Norms 
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Direct 
 
SND2.  Most people who are important to me would think that I 
Should  1 2 3 4 5 6 7 Should not 
have an HPV test to screen for cervical cancer instead of a Pap smear 
 
 
SND3. People who are important to me would expect me to have an HPV test to 
screen for cervical cancer instead of a Pap smear 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
SND4. I would feel under social pressure to have an HPV test to screen for 
cervical cancer instead of a Pap smear 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
 
 
Indirect 
SNI5. My family physician would think that I should have an HPV test to screen 
for cervical cancer instead of a Pap smear 
Unlikely  1 2 3 4 5 6 7 Likely 
 
 
SNI6. What my family physician thinks is important to me 
Not at all 1 2 3 4 5 6 7 Very much  
 
 
SNI7. My friends would think that I should have an HPV test to screen for cervical 
cancer instead of a Pap smear 
Unlikely  1 2 3 4 5 6 7 Likely 
 
 
SNI8. What my friends think is important to me 
Not at all 1  2 3 4 5 6 7 Very much  
 
 
SNI9. My spouse/partner would think that I should have an HPV test to screen for 
cervical cancer instead of a Pap smear 
Unlikely  1 2 3 4 5 6 7 Likely 
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SNI10. What my spouse/partner thinks is important to me 
Not at all 1  2 3 4 5 6 7 Very much  
 
 
SNI11. The BC Cancer Agency would recommend that I should have an HPV 
test to screen for cervical cancer instead of a Pap smear 
Unlikely  1 2 3 4 5 6 7 Likely 
 
 
SNI12. What the BC Cancer Agency recommends is important to me 
Not at all 1  2 3 4 5 6 7 Very much  
 
 
Contacting Partners 
 
CP13. If I had a cervical cancer screening result that showed I had an HPV 
infection, I would feel comfortable sharing the results with my partner(s)  
Unlikely  1 2 3 4 5 6 7 Likely 
 
 
 
CP14. My spouse would be understanding if I had an HPV infection 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
III. Perceived Behavioural Control 
 
 
PBC15. I am confident that I could have an HPV test to screen for cervical 
cancer instead of a Pap smear 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
PBC16. For me to have an HPV test to screen for cervical cancer instead of a 
Pap smear would be 
Easy 1 2 3 4 5 6 7 Difficult 
 
 
PBC17. Whether or not I would have an HPV test to screen for cervical cancer 
instead of a Pap smear would be entirely up to me 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
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PBC18. How much control would you have over whether you had an HPV test to 
screen for cervical cancer instead of a Pap smear?  
No control 1 2 3 4 5 6 7 Complete control. 
 
Preliminary Intention 
 
PI19. I would be willing to have an HPV test to screen for cervical cancer instead 
of a Pap smear 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
IV. Attitudes and Intention 
 
Right now in BC, women start cervical cancer screening once they become 
sexually active. We now know that testing for HPV infections in the cervix is more 
accurate than the Pap smear  for predicting whether or not a woman will develop 
cervical cancer, So, in BC, women would be screened every 4 years with HPV 
testing instead of every year with Pap screening 
 
A20. Having an HPV test to screen for cervical cancer every four years instead 
of a Pap smear every year would be: 
 
Accurate 1 2 3 4 5 6 7 Inaccurate 
Safe  1 2 3 4 5 6 7 Unsafe 
Protect my health 1 2 3 4 5 6 7 Harm my health 
Acceptable  1 2 3 4 5 6 7 Unacceptable 
 
 
IN21. I would be willing to have an HPV test to screen for cervical cancer every 
four years instead of a Pap smear every year  
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
With HPV testing, women would not need to be screened for cervical cancer 
until the age of 25, regardless of when they started being sexually active. 
 
 
A22. Having an HPV test to screen for cervical cancer start after the age of 25 
and every four years instead of a Pap smear every year after becoming 
sexually active would be: 
 
Accurate 1 2 3 4 5 6 7 Inaccurate 
Safe  1 2 3 4 5 6 7 Unsafe 
Protect my health 1 2 3 4 5 6 7 Harm my health 
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Acceptable  1 2 3 4 5 6 7 Unacceptable 
 
 
IN23. I would be willing to have an HPV test to screen for cervical cancer after 
the age of 25 and every four years instead of a Pap smear every year after 
becoming sexually active:   
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
V. Self Collection for HPV 
 
Testing with HPV may offer the opportunity for women to collect their own 
samples for cervical cancer screening by inserting a Q-tip into their vagina.  This 
would mean women would not need to have a clinician take the cervical sample   
 
SC24. Collecting my own sample for cervical cancer screening would be… 
Accurate 1 2 3 4 5 6 7 Inaccurate 
Safe  1 2 3 4 5 6 7 Unsafe 
Protect my health 1 2 3 4 5 6 7 Harm my health 
Acceptable  1 2 3 4 5 6 7 Unacceptable 
 
 
SC25. I would be willing to collect my own sample/specimen for cervical cancer 
screening: 
Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
VI. Involvement in the HPV FOCAL Study 
 
Please answer the following questions about your involvement in the HPV 
FOCAL Study 
 
ST26. As a participant in the HPV FOCAL Study, my knowledge of HPV and its 
relation to cervical cancer has improved 
Strongly disagree   1      2          3     4             5             6            7           
Strongly Agree 
    
 
 
ST27. My involvement in the HPV FOCAL Study has influenced my willingness to 
have an HPV test every 4 years, instead of a Pap smear every year  
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Strongly disagree 1 2 3 4 5 6 7 Strongly 
agree 
 
 
 
Please include my name and phone number in the draw for an iPOD 
Yes No 
 
Name 
Phone number:
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Appendix 2 
 
List of Abbreviations, Definitions, Specifications 
 
Item 
number 
Variable name Survey description: survey items (positive 
orientation) 
A1 Attitudes to HPV 
testing 
Having an HPV test to screen for cervical 
cancer instead of a Pap smear would be: 
 Accurate 
 Safe 
 Protect my health  
 Acceptable   
PI19 Intention to be 
screened for HPV 
I would be willing to have an HPV test to 
screen for cervical cancer instead of a Pap 
smear 
A20 Attitudes to HPV 
testing every four 
years 
Having an HPV test to screen for cervical 
cancer every four years instead of a Pap 
smear every year would be:  
 Accurate 
 Safe 
 Protect my health  
 Acceptable   
IN21 Intention to be 
screened for HPV 
every four years 
I would be willing to have an HPV test to 
screen for cervical cancer every four years 
instead of a Pap smear every year  
A22 Attitudes to HPV 
testing every four 
years and after age 
of 25 
Having an HPV test to screen for cervical 
cancer start after the age of 25 and every 
four years instead of a Pap smear every 
year after becoming sexually active would 
be: 
 Accurate 
 Safe 
 Protect my health  
 Acceptable   
IN23 Intention to be 
screened for HPV 
after the age of 25 
years and every 
four years 
I would be willing to have an HPV test to 
screen for cervical cancer after the age of 
25 and every four years instead of a Pap 
smear every year after becoming sexually 
active  
SND2-
SND3 
Subjective Norms: 
Direct 2/3 
SND2. Most people who are important to me 
would think that I should have an HPV test 
to screen for cervical cancer instead of a Pap 
smear 
 
SND3. People who are important to me 
would expect me to have an HPV test to 
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screen for cervical cancer instead of a Pap 
smear 
 
SNI5-
SNI12 
Subjective Norms: 
Indirect 
SNI 5/6. My family physician would think 
that I should have an HPV test to screen for 
cervical cancer instead of a Pap smear & 
What my family physician thinks is important 
to me 
 
SNI 7/8. My friends would think that I should 
have an HPV test to screen for cervical 
cancer instead of a Pap smear & What my 
friends think is important to me 
 
SNI 9/10. My spouse/partner would think 
that I should have an HPV test to screen for 
cervical cancer instead of a Pap smear & 
What my spouse/partner thinks is important 
to me 
 
SNI 11/12. The BC Cancer Agency would 
recommend that I should have an HPV test 
to screen for cervical cancer instead of a Pap 
smear & What the BC Cancer Agency 
recommends is important to me 
 
CP13-
CP14 
Contacting partners CP13. If I had a cervical cancer screening 
result that showed I had an HPV infection, I 
would feel comfortable sharing the results 
with my partner(s)  
 
CP14. My spouse would be understanding if I 
had an HPV infection 
PBC15-
PBC18 
Perceived 
behavioural control 
PBC 15. I am confident that I could have an 
HPV test to screen for cervical cancer 
instead of a Pap smear 
 
PBC 16. For me to have an HPV test to 
screen for cervical cancer instead of a Pap 
smear would be easy 
 
PBC 17. Whether or not I would have an 
HPV test to screen for cervical cancer 
instead of a Pap smear would be entirely up 
to me 
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PBC 18. How much control would you have 
over whether you had an HPV test to screen 
for cervical cancer instead of a Pap smear?  
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